Long-Term Immunogenicity of the Norovirus GI.1/GII.4 Bivalent Virus-like Particle (VLP) Vaccine (NoV Vaccine) in Adults

A Phase 2, Long-Term Immunogenicity Follow-up Trial of Adult and Elderly Subjects Who Have Previously Received an Intramuscular Injection of Norovirus GI.1/GII.4 Bivalent Virus-Like Particle Vaccine

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03039790

Enrollment

528

Registered

2017-02-01

Start date

2017-02-21

Completion date

2021-07-22

Last updated

2022-11-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy Volunteers, Norovirus

Keywords

Drug Therapy

Brief summary

The purpose of this study is to evaluate descriptively the long-term immunogenicity of at least 1 NoV vaccine administration.

Detailed description

Results prepared and posted by Takeda on behalf of Hillevax, the IND holder. The drug being tested in this study is called NoV vaccine. NoV vaccine is being tested for protection against acute gastroenteritis (AGE) due to norovirus. The study will enroll maximum of approximately 575 participants. Participants who previously received NoV vaccine in studies NOR-107, NOR-210 and NOR-204 will be enrolled. Participants from study NOR-107 will enter the study at the time of their 3rd year post-primary vaccination, and from studies NOR-210 and NOR-204, at their 2nd year post-primary vaccination. The duration of participation in the study will be different for each participant. This multi-center trial will be conducted in Belgium and the United States. The overall time to participate in this study is maximum 5 years after primary NoV vaccination. Participants will have a maximum of 4 visits over 3 years

Interventions

BIOLOGICALNoV Vaccine

NoV vaccine injection administered.

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

PREVENTION

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

1\. Male and female participants who previously received at least 1 dose of NoV vaccine in trials NOR-107 (NCT02038907), NOR-210 (NCT02475278) and NOR-204 (NCT02661490), have baseline and post-vaccination data, and completed the primary vaccination trial protocol as initially described.

Exclusion criteria

1. Participation in any clinical trial is allowed, on condition that no investigational product is administered within 30 days prior to blood sampling. 2. In the opinion of the investigator, the participant is not medically eligible to provide blood specimens. 3. Individuals with behavioral or cognitive impairment or psychiatric disease that, in the opinion of the investigator, may interfere with the participant's ability to participate in the trial.

Design outcomes

Primary

Measure	Time frame	Description
Geometric Mean Blocking Titers 50 Percent (%) (GMBT50) of Anti-norovirus GI.1 VLP Antibodies as Measured by Histo-Blood Group Antigen HBGA Blocking Assay	Baseline up to Year 2 post-primary vaccination of initial study NOR-107, NOR-210 NOR-204 and up to Year 5 of this extension study	GMBT50 of anti-norovirus GI. VLP antibody titers as measured by the histo-blood group antigen (HBGA) blocking assay. Data reported for up to Year 5 was collected at Baseline (NOR-107, NOR-210, NOR-204) , at Days 28 (NOR-107), 29 (NOR-204 and NOR-210), Day 36 (NOR-204), Day 56 (NOR-107) and Day 57 (NOR-204), Day 208 (NOR-107) and Day 211 (NOR-204), Year 2 (NOR-204 and NOR-210) Years 3, 4 and 5 (NOR-107, NOR-210, NOR-204)
Geometric Mean Blocking Titer (GMBT50) of Anti-norovirus GII.4 VLP Antibodies as Measured by HBGA Blocking Assay	Baseline up to Year 2 post-primary vaccination of initial study NOR-107, NOR-210 NOR-204 and up to Year 5 of this extension study	GMBT50 of anti-norovirus GII.4 VLP antibody titers as measured by the HBGA blocking assay. Data reported for up to Year 5 was collected at Baseline (NOR-107, NOR-210, NOR-204), at Days 28 (NOR-107), 29 (NOR-204 and NOR-210), Day 36 (NOR-204), Day 56 (NOR-107) and Day 57 (NOR-204), Day 208 (NOR-107) and Day 211 (NOR-204), Year 2 (NOR-204 and NOR-210) Years 3 4 and 5 (NOR-107,NOR-210, NOR-204) .

Secondary

Measure	Time frame	Description
Geometric Mean Titers (GMT) of Anti-norovirus GI.1 VLP Antibodies as Measured by Total Immunoglobulin (Pan-Ig) Enzyme-linked Immunosorbent Assay (ELISA)	Baseline up to Year 2 post-primary vaccination of initial study NOR-107, NOR-210 NOR-204 and up to Year 5 of this extension study	GMT of anti-norovirus GI.1 VLP antibody titers as measured by total immunoglobulin (pan-Ig) enzyme-linked immunoassay (ELISA). Data reported for up to Year 5 was collected at Baseline (NOR-107, NOR-210, NOR-204), at Days 28 (NOR-107), 29 (NOR-204 and NOR-210), Day 36 (NOR-204), Day 56 (NOR-107) and Day 57 (NOR-204), Day 208 (NOR-107) and Day 211 (NOR-204), Year 2 (NOR-204 and NOR-210) Years 3, 4 and 5(NOR-107,NOR-210, NOR-204).
Geometric Mean Titers (GMT) of Anti-norovirus GII.4 VLP Antibodies as Measured by Pan-Ig ELISA	Baseline up to Year 2 post-primary vaccination of initial study NOR-107, NOR-210 NOR-204 and up to Year 5 of this extension study	GMT of anti-norovirus GII.4 VLP antibody titers as measured by pan-Ig ELISA. Data reported for up to Year 5 was collected at Baseline (NOR-107,NOR-210, NOR-204), at Days 28 (NOR-107), 29 (NOR-204 and NOR-210), Day 36 (NOR-204), Day 56 (NOR-107) and Day 57 (NOR-204), Day 208 (NOR-107) and Day 211 (NOR-204), Year 2 (NOR-204 and NOR-210) Years 3, 4 and 5 (NOR-107,NOR-210, NOR-204).

Countries

Belgium, United States

Participant flow

Participants by arm

Arm	Count
NOR-107: GI.1/GII.4 (15/15/500) μg- MPL 50 μg,1-Dose Eligible NOR-107 participants who had received Hepatitis A vaccine, intramuscular (IM), on Day 1, followed by norovirus bivalent virus like particle (VLP) vaccine (15 µg of GI.1 norovirus virus VLP and 15 µg GII.4 norovirus VLP) adjuvanted with 50 µg monophosphoryl lipid A (MPL) and 500 µg aluminium hydroxide, on Day 28 were enrolled at 3rd year post-primary vaccination in NOR-213 study.	25
NOR-107: GI.1/GII.4 (15/50/500) μg- MPL 50 μg,1-Dose Eligible NOR-107 participants who had received Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 µg of GI.1 norovirus VLP and 50 µg GII.4 norovirus VLP) adjuvanted with 50 µg MPL and 500 µg aluminium hydroxide, on Day 28 were enrolled at 3rd year post-primary vaccination in NOR-213 study.	19
NOR-107: GI.1/GII.4 (50/50/500) μg- MPL 50 μg,1-Dose Eligible NOR-107 participants who had received Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (50 µg of GI.1 norovirus VLP and 50 µg GII.4 norovirus VLP) adjuvanted with 50 µg MPL and 500 µg aluminium hydroxide, on Day 28 were enrolled at 3rd year post-primary vaccination in NOR-213 study.	27
NOR-107: GI.1/GII.4 (15/15/500) μg- MPL 15 μg,1-Dose Eligible NOR-107 participants who had received Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 µg of GI.1 norovirus VLP and 15 µg GII.4 norovirus VLP) adjuvanted with 15 µg MPL and 500 µg aluminium hydroxide, on Day 28 were enrolled at 3rd year post-primary vaccination in NOR-213 study.	27
NOR-107: GI.1/GII.4 (15/50/500) μg- MPL 15 μg,1-Dose Eligible NOR-107 participants who had received IM hepatitis A vaccine on Day 1, followed by IM norovirus bivalent vaccine (15 µg of GI.1 norovirus VLP and 50 µg GII.4 norovirus VLP) adjuvanted with 15 µg MPL and 500 µg aluminium hydroxide, on Day 28 were enrolled at 3rd year post-primary vaccination in NOR-213 study.	23
NOR-107: GI.1/GII.4 (50/50/500) μg- MPL 15 μg,1-Dose Eligible NOR-107 participants who had received Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (50 µg of GI.1 norovirus VLP and 50 µg GII.4 norovirus VLP) adjuvanted with 15 µg MPL and 500 µg aluminium hydroxide, on Day 28 were enrolled at 3rd year post-primary vaccination in NOR-213 study.	27
NOR-107: GI.1/GII.4 (15/50/500) μg,1-Dose Eligible NOR-107 participants who had received Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 µg of GI.1 norovirus VLP and 15 µg GII.4 norovirus VLP) adjuvanted with 500 µg aluminium hydroxide, on Day 28 were enrolled at 3rd year post-primary vaccination in NOR-213 study.	25
NOR-107: GI.1/GII.4 (50/50/500) μg,1-Dose Eligible NOR-107 participants who had received Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 µg of GI.1 norovirus VLP and 50 µg GII.4 norovirus VLP) adjuvanted with 500 µg aluminium hydroxide, on Day 28 were enrolled at 3rd year post-primary vaccination in NOR-213 study.	28
NOR-107: GI.1/GII.4 (50/150/500) μg,1-Dose Eligible NOR-107 participants who had received Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (50 µg of GI.1 norovirus VLP and 50 µg GII.4 norovirus VLP) adjuvanted with 500 µg aluminium hydroxide, on Day 28 were enrolled at 3rd year post-primary vaccination in NOR-213 study.	22
NOR-107: GI.1/GII.4 (15/50/167) μg,1-Dose Eligible NOR-107 participants who had received Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (50 µg of GI.1 norovirus VLP and 150 µg GII.4 norovirus VLP) adjuvanted with 500 µg aluminium hydroxide, on Day 28 were enrolled at 3rd year post-primary vaccination in NOR-213 study.	28
NOR-107: GI.1/GII.4 (15/150/167) μg,1-Dose Eligible NOR-107 participants who had received Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 µg of GI.1 norovirus VLP and 50 µg GII.4 norovirus VLP) adjuvanted with 167 µg aluminium hydroxide, on Day 28 were enrolled at 3rd year post-primary vaccination in NOR-213 study.	21
NOR-107: GI.1/GII.4 (15/50/500) μg,2-Dose Eligible NOR-107 participants who had received Norovirus bivalent VLP vaccine (15 µg of GI.1 norovirus VLP and 50 µg GII.4 norovirus VLP) adjuvanted with 500 µg aluminium hydroxide, IM, on Day 1 and Day 28 were enrolled at 3rd year post-primary vaccination in NOR-213 study.	25
NOR-107: GI.1/GII.4 (50/150/500) μg,2-Dose Eligible NOR-107 participants who had received Norovirus bivalent VLP vaccine (50 µg of GI.1 norovirus VLP and 150 µg GII.4 norovirus VLP) adjuvanted with 500 µg aluminium hydroxide, IM, on Day 1 and Day 28 were enrolled at 3rd year post-primary vaccination in NOR-213 study.	24
NOR-107: GI.1/GII.4 (15/50/167) μg,2-Dose Eligible NOR-107 participants who had received Norovirus bivalent VLP vaccine (15 µg of GI.1 norovirus VLP and 50 µg GII.4 norovirus VLP) adjuvanted with 167 µg aluminium hydroxide, IM, on Day 1 and Day 28 were enrolled at 3rd year post-primary vaccination in NOR-213 study.	24
NOR-210: GI.1/GII.4 (15/50/500) µg, 1-Dose Eligible NOR-210 participants who had received Norovirus GI.1/GII.4 bivalent VLP vaccine NoV Vaccine (15 µg of GI.1 norovirus VLP and 50 µg GII.4 norovirus VLP, adjuvanted with 500 µg aluminium hydroxide), IM injection, once on Day 1 were enrolled at 2nd year post-primary vaccination in NOR-213 study.	24
NOR-204: GI.1/GII.4 (15/50/500) µg - MPL 15 µg, 1-Dose Eligible NOR-204 participants who had received Norovirus bivalent placebo-matching vaccine, intramuscularly (IM), on Day 1, followed by norovirus (NoV) \[15 μg of GI.1 and 50 μg of GII.4 bivalent virus-like particle (VLP)\] adjuvanted with 500 µg aluminium hydroxide and 15 μg of monophosphoryl lipid A (MPL) (Composition B), on Day 29 were enrolled at 2nd year post-primary vaccination in NOR-213 study.	29
NOR-204: GI.1/GII.4 (15/50/500) µg, 1-Dose (Age: 60-94 Yrs) Eligible NOR-204 participants of age 60-94 years who had received Norovirus bivalent placebo-matching vaccine, IM, on Day 1, followed by norovirus (NoV) \[15 μg of GI.1 and 50 μg of GII.4 bivalent virus-like particle (VLP)\] adjuvanted with 500 µg aluminium hydroxide (Composition A), on Day 29 were enrolled at 2nd year post-primary vaccination in NOR-213 study.	39
NOR-204: GI.1/GII.4 (15/50/500) µg, 1-Dose (Age: 18-49 Yrs) Eligible NOR-204 participants of age 18-49 years who had received Norovirus bivalent placebo-matching vaccine, IM, on Day 1, followed by norovirus (NoV) \[15 μg of GI.1 and 50 μg of GII.4 bivalent virus-like particle (VLP)\] adjuvanted with 500 µg aluminium hydroxide (Composition A), on Day 29 were enrolled at 2nd year post-primary vaccination in NOR-213 study.	14
NOR-204: GI.1/GII.4 (15/50/500) µg - MPL 15 µg, 2-Dose Eligible NOR-204 participants who had received Norovirus bivalent VLP vaccine (15 µg of GI.1 norovirus VLP and 50 µg GII.4 norovirus VLP) adjuvanted with 500 µg aluminium hydroxide and 15 μg of MPL (Composition B), IM, on Day 1 and Day 29 were enrolled at 2nd year post-primary vaccination in NOR-213 study.	35
NOR-204: GI.1/GII.4 (15/50/500) µg, 2-Dose Eligible NOR-204 participants who had received Norovirus bivalent placebo-matching vaccine (15 μg of GI.1 50 μg of GII.4 bivalent VLP) adjuvanted with 500 µg aluminium hydroxide (Composition A) IM, on Day 1 and Day 29 were enrolled at 2nd year post-primary vaccination in NOR-213 study.	42
Total	528

Withdrawals & dropouts

Period	Reason	FG000	FG002	FG003	FG005	FG006	FG007	FG009	FG010	FG012	FG014	FG015	FG016	FG017	FG018	FG019
Overall Study	Death	0	0	0	0	0	0	0	0	0	0	1	3	0	2	0
Overall Study	Lost to Follow-up	2	1	1	1	1	1	1	1	1	3	1	2	2	1	3
Overall Study	Reason, not Specified	1	0	0	0	0	0	0	0	0	0	0	2	0	1	0
Overall Study	Withdrawal of Consent	1	0	1	0	0	0	1	0	2	1	5	3	0	2	5

Baseline characteristics

Characteristic	NOR-107: GI.1/GII.4 (15/15/500) μg- MPL 50 μg,1-Dose	Total	NOR-204: GI.1/GII.4 (15/50/500) µg, 2-Dose	NOR-204: GI.1/GII.4 (15/50/500) µg - MPL 15 µg, 2-Dose	NOR-204: GI.1/GII.4 (15/50/500) µg, 1-Dose (Age: 18-49 Yrs)	NOR-204: GI.1/GII.4 (15/50/500) µg, 1-Dose (Age: 60-94 Yrs)	NOR-204: GI.1/GII.4 (15/50/500) µg - MPL 15 µg, 1-Dose	NOR-210: GI.1/GII.4 (15/50/500) µg, 1-Dose	NOR-107: GI.1/GII.4 (15/50/167) μg,2-Dose	NOR-107: GI.1/GII.4 (50/150/500) μg,2-Dose	NOR-107: GI.1/GII.4 (15/50/500) μg,2-Dose	NOR-107: GI.1/GII.4 (15/150/167) μg,1-Dose	NOR-107: GI.1/GII.4 (15/50/167) μg,1-Dose	NOR-107: GI.1/GII.4 (50/150/500) μg,1-Dose	NOR-107: GI.1/GII.4 (50/50/500) μg,1-Dose	NOR-107: GI.1/GII.4 (15/50/500) μg,1-Dose	NOR-107: GI.1/GII.4 (50/50/500) μg- MPL 15 μg,1-Dose	NOR-107: GI.1/GII.4 (15/50/500) μg- MPL 15 μg,1-Dose	NOR-107: GI.1/GII.4 (15/15/500) μg- MPL 15 μg,1-Dose	NOR-107: GI.1/GII.4 (50/50/500) μg- MPL 50 μg,1-Dose	NOR-107: GI.1/GII.4 (15/50/500) μg- MPL 50 μg,1-Dose
Age, Continuous	48.1 years STANDARD_DEVIATION 14.24	53.6 years STANDARD_DEVIATION 18.82	76.1 years STANDARD_DEVIATION 8.41	76.9 years STANDARD_DEVIATION 9.94	35.6 years STANDARD_DEVIATION 7.27	77.2 years STANDARD_DEVIATION 9.48	73.6 years STANDARD_DEVIATION 8.5	35.0 years STANDARD_DEVIATION 9.44	46.3 years STANDARD_DEVIATION 15.17	47.3 years STANDARD_DEVIATION 13.98	42.6 years STANDARD_DEVIATION 13.33	41.9 years STANDARD_DEVIATION 16.17	44.0 years STANDARD_DEVIATION 15.2	45.5 years STANDARD_DEVIATION 13.23	46.8 years STANDARD_DEVIATION 13.59	45.4 years STANDARD_DEVIATION 13.63	48.0 years STANDARD_DEVIATION 13.13	48.0 years STANDARD_DEVIATION 13.49	47.5 years STANDARD_DEVIATION 13.96	46.8 years STANDARD_DEVIATION 13.39	47.9 years STANDARD_DEVIATION 14.6
Ethnicity (NIH/OMB) Hispanic or Latino	0 Participants	15 Participants	3 Participants	3 Participants	1 Participants	2 Participants	1 Participants	5 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants
Ethnicity (NIH/OMB) Not Hispanic or Latino	0 Participants	168 Participants	39 Participants	32 Participants	13 Participants	37 Participants	28 Participants	19 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants
Ethnicity (NIH/OMB) Unknown or Not Reported	25 Participants	345 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	24 Participants	24 Participants	25 Participants	21 Participants	28 Participants	22 Participants	28 Participants	25 Participants	27 Participants	23 Participants	27 Participants	27 Participants	19 Participants
Race (NIH/OMB) American Indian or Alaska Native	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants
Race (NIH/OMB) Asian	0 Participants	4 Participants	0 Participants	0 Participants	0 Participants	1 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	1 Participants	0 Participants	0 Participants	0 Participants	1 Participants	0 Participants	1 Participants	0 Participants	0 Participants
Race (NIH/OMB) Black or African American	0 Participants	12 Participants	3 Participants	0 Participants	1 Participants	0 Participants	1 Participants	7 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants
Race (NIH/OMB) More than one race	0 Participants	1 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	1 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants
Race (NIH/OMB) Native Hawaiian or Other Pacific Islander	0 Participants	1 Participants	0 Participants	0 Participants	1 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants
Race (NIH/OMB) Unknown or Not Reported	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants
Race (NIH/OMB) White	25 Participants	510 Participants	39 Participants	35 Participants	12 Participants	38 Participants	28 Participants	16 Participants	24 Participants	24 Participants	25 Participants	21 Participants	27 Participants	22 Participants	28 Participants	25 Participants	26 Participants	23 Participants	26 Participants	27 Participants	19 Participants
Region of Enrollment Belgium	25 Participants	345 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	24 Participants	24 Participants	25 Participants	21 Participants	28 Participants	22 Participants	28 Participants	25 Participants	27 Participants	23 Participants	27 Participants	27 Participants	19 Participants
Region of Enrollment United States	0 Participants	183 Participants	42 Participants	35 Participants	14 Participants	39 Participants	29 Participants	24 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants
Sex: Female, Male Female	16 Participants	324 Participants	23 Participants	18 Participants	7 Participants	19 Participants	20 Participants	10 Participants	16 Participants	18 Participants	15 Participants	12 Participants	21 Participants	16 Participants	14 Participants	12 Participants	21 Participants	14 Participants	20 Participants	19 Participants	13 Participants
Sex: Female, Male Male	9 Participants	204 Participants	19 Participants	17 Participants	7 Participants	20 Participants	9 Participants	14 Participants	8 Participants	6 Participants	10 Participants	9 Participants	7 Participants	6 Participants	14 Participants	13 Participants	6 Participants	9 Participants	7 Participants	8 Participants	6 Participants

Adverse events

Event type	EG000 affected / at risk	EG001 affected / at risk	EG002 affected / at risk	EG003 affected / at risk	EG004 affected / at risk	EG005 affected / at risk	EG006 affected / at risk	EG007 affected / at risk	EG008 affected / at risk	EG009 affected / at risk	EG010 affected / at risk	EG011 affected / at risk	EG012 affected / at risk	EG013 affected / at risk	EG014 affected / at risk	EG015 affected / at risk	EG016 affected / at risk	EG017 affected / at risk	EG018 affected / at risk	EG019 affected / at risk
deaths Total, all-cause mortality	0 / 25	0 / 19	0 / 27	0 / 27	0 / 23	0 / 27	0 / 25	0 / 28	0 / 22	0 / 28	0 / 21	0 / 25	0 / 24	0 / 24	0 / 24	1 / 29	3 / 39	0 / 14	2 / 35	0 / 42
other Total, other adverse events	0 / 25	0 / 19	0 / 27	0 / 27	0 / 23	0 / 27	0 / 25	0 / 28	0 / 22	0 / 28	0 / 21	0 / 25	0 / 24	0 / 24	0 / 24	0 / 29	0 / 39	0 / 14	0 / 35	0 / 42
serious Total, serious adverse events	0 / 25	1 / 19	1 / 27	1 / 27	0 / 23	0 / 27	0 / 25	0 / 28	0 / 22	0 / 28	0 / 21	0 / 25	0 / 24	0 / 24	1 / 24	2 / 29	5 / 39	0 / 14	2 / 35	2 / 42

Outcome results

Primary

Geometric Mean Blocking Titer (GMBT50) of Anti-norovirus GII.4 VLP Antibodies as Measured by HBGA Blocking Assay

GMBT50 of anti-norovirus GII.4 VLP antibody titers as measured by the HBGA blocking assay. Data reported for up to Year 5 was collected at Baseline (NOR-107, NOR-210, NOR-204), at Days 28 (NOR-107), 29 (NOR-204 and NOR-210), Day 36 (NOR-204), Day 56 (NOR-107) and Day 57 (NOR-204), Day 208 (NOR-107) and Day 211 (NOR-204), Year 2 (NOR-204 and NOR-210) Years 3 4 and 5 (NOR-107,NOR-210, NOR-204) .

Time frame: Baseline up to Year 2 post-primary vaccination of initial study NOR-107, NOR-210 NOR-204 and up to Year 5 of this extension study

Population: PPS included all participants in the FAS who had no major or critical protocol violations that potentially confound the primary endpoint. Number analyzed is the number of participants with data available for analysis at specific timepoints.

Arm	Measure	Group	Value (GEOMETRIC_MEAN)
NOR-107: GI.1/GII.4 (15/15/500) μg- MPL 50 μg,1-Dose	Geometric Mean Blocking Titer (GMBT50) of Anti-norovirus GII.4 VLP Antibodies as Measured by HBGA Blocking Assay	Day 56	367.9 titer
NOR-107: GI.1/GII.4 (15/15/500) μg- MPL 50 μg,1-Dose	Geometric Mean Blocking Titer (GMBT50) of Anti-norovirus GII.4 VLP Antibodies as Measured by HBGA Blocking Assay	Year 3	122.7 titer
NOR-107: GI.1/GII.4 (15/15/500) μg- MPL 50 μg,1-Dose	Geometric Mean Blocking Titer (GMBT50) of Anti-norovirus GII.4 VLP Antibodies as Measured by HBGA Blocking Assay	Year 4	85.7 titer
NOR-107: GI.1/GII.4 (15/15/500) μg- MPL 50 μg,1-Dose	Geometric Mean Blocking Titer (GMBT50) of Anti-norovirus GII.4 VLP Antibodies as Measured by HBGA Blocking Assay	Year 5	101.1 titer
NOR-107: GI.1/GII.4 (15/15/500) μg- MPL 50 μg,1-Dose	Geometric Mean Blocking Titer (GMBT50) of Anti-norovirus GII.4 VLP Antibodies as Measured by HBGA Blocking Assay	Day 208	216.4 titer
NOR-107: GI.1/GII.4 (15/15/500) μg- MPL 50 μg,1-Dose	Geometric Mean Blocking Titer (GMBT50) of Anti-norovirus GII.4 VLP Antibodies as Measured by HBGA Blocking Assay	Baseline	74.8 titer
NOR-107: GI.1/GII.4 (15/15/500) μg- MPL 50 μg,1-Dose	Geometric Mean Blocking Titer (GMBT50) of Anti-norovirus GII.4 VLP Antibodies as Measured by HBGA Blocking Assay	Day 28	80.7 titer
NOR-107: GI.1/GII.4 (15/50/500) μg- MPL 50 μg,1-Dose	Geometric Mean Blocking Titer (GMBT50) of Anti-norovirus GII.4 VLP Antibodies as Measured by HBGA Blocking Assay	Day 28	67.2 titer
NOR-107: GI.1/GII.4 (15/50/500) μg- MPL 50 μg,1-Dose	Geometric Mean Blocking Titer (GMBT50) of Anti-norovirus GII.4 VLP Antibodies as Measured by HBGA Blocking Assay	Baseline	77.4 titer
NOR-107: GI.1/GII.4 (15/50/500) μg- MPL 50 μg,1-Dose	Geometric Mean Blocking Titer (GMBT50) of Anti-norovirus GII.4 VLP Antibodies as Measured by HBGA Blocking Assay	Day 56	755.9 titer
NOR-107: GI.1/GII.4 (15/50/500) μg- MPL 50 μg,1-Dose	Geometric Mean Blocking Titer (GMBT50) of Anti-norovirus GII.4 VLP Antibodies as Measured by HBGA Blocking Assay	Year 3	177.1 titer
NOR-107: GI.1/GII.4 (15/50/500) μg- MPL 50 μg,1-Dose	Geometric Mean Blocking Titer (GMBT50) of Anti-norovirus GII.4 VLP Antibodies as Measured by HBGA Blocking Assay	Year 4	122.8 titer
NOR-107: GI.1/GII.4 (15/50/500) μg- MPL 50 μg,1-Dose	Geometric Mean Blocking Titer (GMBT50) of Anti-norovirus GII.4 VLP Antibodies as Measured by HBGA Blocking Assay	Year 5	138.3 titer
NOR-107: GI.1/GII.4 (15/50/500) μg- MPL 50 μg,1-Dose	Geometric Mean Blocking Titer (GMBT50) of Anti-norovirus GII.4 VLP Antibodies as Measured by HBGA Blocking Assay	Day 208	290.1 titer
NOR-107: GI.1/GII.4 (50/50/500) μg- MPL 50 μg,1-Dose	Geometric Mean Blocking Titer (GMBT50) of Anti-norovirus GII.4 VLP Antibodies as Measured by HBGA Blocking Assay	Baseline	116.8 titer
NOR-107: GI.1/GII.4 (50/50/500) μg- MPL 50 μg,1-Dose	Geometric Mean Blocking Titer (GMBT50) of Anti-norovirus GII.4 VLP Antibodies as Measured by HBGA Blocking Assay	Day 56	425.1 titer
NOR-107: GI.1/GII.4 (50/50/500) μg- MPL 50 μg,1-Dose	Geometric Mean Blocking Titer (GMBT50) of Anti-norovirus GII.4 VLP Antibodies as Measured by HBGA Blocking Assay	Year 3	117.9 titer
NOR-107: GI.1/GII.4 (50/50/500) μg- MPL 50 μg,1-Dose	Geometric Mean Blocking Titer (GMBT50) of Anti-norovirus GII.4 VLP Antibodies as Measured by HBGA Blocking Assay	Year 4	90.8 titer
NOR-107: GI.1/GII.4 (50/50/500) μg- MPL 50 μg,1-Dose	Geometric Mean Blocking Titer (GMBT50) of Anti-norovirus GII.4 VLP Antibodies as Measured by HBGA Blocking Assay	Day 208	231.4 titer
NOR-107: GI.1/GII.4 (50/50/500) μg- MPL 50 μg,1-Dose	Geometric Mean Blocking Titer (GMBT50) of Anti-norovirus GII.4 VLP Antibodies as Measured by HBGA Blocking Assay	Day 28	128.0 titer
NOR-107: GI.1/GII.4 (50/50/500) μg- MPL 50 μg,1-Dose	Geometric Mean Blocking Titer (GMBT50) of Anti-norovirus GII.4 VLP Antibodies as Measured by HBGA Blocking Assay	Year 5	124.4 titer
NOR-107: GI.1/GII.4 (15/15/500) μg- MPL 15 μg,1-Dose	Geometric Mean Blocking Titer (GMBT50) of Anti-norovirus GII.4 VLP Antibodies as Measured by HBGA Blocking Assay	Year 5	91.2 titer
NOR-107: GI.1/GII.4 (15/15/500) μg- MPL 15 μg,1-Dose	Geometric Mean Blocking Titer (GMBT50) of Anti-norovirus GII.4 VLP Antibodies as Measured by HBGA Blocking Assay	Day 56	277.9 titer
NOR-107: GI.1/GII.4 (15/15/500) μg- MPL 15 μg,1-Dose	Geometric Mean Blocking Titer (GMBT50) of Anti-norovirus GII.4 VLP Antibodies as Measured by HBGA Blocking Assay	Year 4	79.5 titer
NOR-107: GI.1/GII.4 (15/15/500) μg- MPL 15 μg,1-Dose	Geometric Mean Blocking Titer (GMBT50) of Anti-norovirus GII.4 VLP Antibodies as Measured by HBGA Blocking Assay	Year 3	104.0 titer
NOR-107: GI.1/GII.4 (15/15/500) μg- MPL 15 μg,1-Dose	Geometric Mean Blocking Titer (GMBT50) of Anti-norovirus GII.4 VLP Antibodies as Measured by HBGA Blocking Assay	Baseline	72.1 titer
NOR-107: GI.1/GII.4 (15/15/500) μg- MPL 15 μg,1-Dose	Geometric Mean Blocking Titer (GMBT50) of Anti-norovirus GII.4 VLP Antibodies as Measured by HBGA Blocking Assay	Day 208	176.2 titer
NOR-107: GI.1/GII.4 (15/15/500) μg- MPL 15 μg,1-Dose	Geometric Mean Blocking Titer (GMBT50) of Anti-norovirus GII.4 VLP Antibodies as Measured by HBGA Blocking Assay	Day 28	71.3 titer
NOR-107: GI.1/GII.4 (15/50/500) μg- MPL 15 μg,1-Dose	Geometric Mean Blocking Titer (GMBT50) of Anti-norovirus GII.4 VLP Antibodies as Measured by HBGA Blocking Assay	Year 4	61.7 titer
NOR-107: GI.1/GII.4 (15/50/500) μg- MPL 15 μg,1-Dose	Geometric Mean Blocking Titer (GMBT50) of Anti-norovirus GII.4 VLP Antibodies as Measured by HBGA Blocking Assay	Year 5	71.3 titer
NOR-107: GI.1/GII.4 (15/50/500) μg- MPL 15 μg,1-Dose	Geometric Mean Blocking Titer (GMBT50) of Anti-norovirus GII.4 VLP Antibodies as Measured by HBGA Blocking Assay	Day 28	64.9 titer
NOR-107: GI.1/GII.4 (15/50/500) μg- MPL 15 μg,1-Dose	Geometric Mean Blocking Titer (GMBT50) of Anti-norovirus GII.4 VLP Antibodies as Measured by HBGA Blocking Assay	Day 56	584.7 titer
NOR-107: GI.1/GII.4 (15/50/500) μg- MPL 15 μg,1-Dose	Geometric Mean Blocking Titer (GMBT50) of Anti-norovirus GII.4 VLP Antibodies as Measured by HBGA Blocking Assay	Year 3	80.5 titer
NOR-107: GI.1/GII.4 (15/50/500) μg- MPL 15 μg,1-Dose	Geometric Mean Blocking Titer (GMBT50) of Anti-norovirus GII.4 VLP Antibodies as Measured by HBGA Blocking Assay	Baseline	54.6 titer
NOR-107: GI.1/GII.4 (15/50/500) μg- MPL 15 μg,1-Dose	Geometric Mean Blocking Titer (GMBT50) of Anti-norovirus GII.4 VLP Antibodies as Measured by HBGA Blocking Assay	Day 208	215.9 titer
NOR-107: GI.1/GII.4 (50/50/500) μg- MPL 15 μg,1-Dose	Geometric Mean Blocking Titer (GMBT50) of Anti-norovirus GII.4 VLP Antibodies as Measured by HBGA Blocking Assay	Day 56	593.4 titer
NOR-107: GI.1/GII.4 (50/50/500) μg- MPL 15 μg,1-Dose	Geometric Mean Blocking Titer (GMBT50) of Anti-norovirus GII.4 VLP Antibodies as Measured by HBGA Blocking Assay	Year 3	125.9 titer
NOR-107: GI.1/GII.4 (50/50/500) μg- MPL 15 μg,1-Dose	Geometric Mean Blocking Titer (GMBT50) of Anti-norovirus GII.4 VLP Antibodies as Measured by HBGA Blocking Assay	Year 4	106.7 titer
NOR-107: GI.1/GII.4 (50/50/500) μg- MPL 15 μg,1-Dose	Geometric Mean Blocking Titer (GMBT50) of Anti-norovirus GII.4 VLP Antibodies as Measured by HBGA Blocking Assay	Day 208	247.4 titer
NOR-107: GI.1/GII.4 (50/50/500) μg- MPL 15 μg,1-Dose	Geometric Mean Blocking Titer (GMBT50) of Anti-norovirus GII.4 VLP Antibodies as Measured by HBGA Blocking Assay	Year 5	103.2 titer
NOR-107: GI.1/GII.4 (50/50/500) μg- MPL 15 μg,1-Dose	Geometric Mean Blocking Titer (GMBT50) of Anti-norovirus GII.4 VLP Antibodies as Measured by HBGA Blocking Assay	Day 28	101.3 titer
NOR-107: GI.1/GII.4 (50/50/500) μg- MPL 15 μg,1-Dose	Geometric Mean Blocking Titer (GMBT50) of Anti-norovirus GII.4 VLP Antibodies as Measured by HBGA Blocking Assay	Baseline	104.2 titer
NOR-107: GI.1/GII.4 (15/15/500) μg,1-Dose	Geometric Mean Blocking Titer (GMBT50) of Anti-norovirus GII.4 VLP Antibodies as Measured by HBGA Blocking Assay	Year 5	94.3 titer
NOR-107: GI.1/GII.4 (15/15/500) μg,1-Dose	Geometric Mean Blocking Titer (GMBT50) of Anti-norovirus GII.4 VLP Antibodies as Measured by HBGA Blocking Assay	Day 28	69.7 titer
NOR-107: GI.1/GII.4 (15/15/500) μg,1-Dose	Geometric Mean Blocking Titer (GMBT50) of Anti-norovirus GII.4 VLP Antibodies as Measured by HBGA Blocking Assay	Baseline	77.5 titer
NOR-107: GI.1/GII.4 (15/15/500) μg,1-Dose	Geometric Mean Blocking Titer (GMBT50) of Anti-norovirus GII.4 VLP Antibodies as Measured by HBGA Blocking Assay	Day 56	201.9 titer
NOR-107: GI.1/GII.4 (15/15/500) μg,1-Dose	Geometric Mean Blocking Titer (GMBT50) of Anti-norovirus GII.4 VLP Antibodies as Measured by HBGA Blocking Assay	Day 208	150.4 titer
NOR-107: GI.1/GII.4 (15/15/500) μg,1-Dose	Geometric Mean Blocking Titer (GMBT50) of Anti-norovirus GII.4 VLP Antibodies as Measured by HBGA Blocking Assay	Year 4	108.6 titer
NOR-107: GI.1/GII.4 (15/15/500) μg,1-Dose	Geometric Mean Blocking Titer (GMBT50) of Anti-norovirus GII.4 VLP Antibodies as Measured by HBGA Blocking Assay	Year 3	121.2 titer
NOR-107: GI.1/GII.4 (15/50/500) μg,1-Dose	Geometric Mean Blocking Titer (GMBT50) of Anti-norovirus GII.4 VLP Antibodies as Measured by HBGA Blocking Assay	Year 5	144.9 titer
NOR-107: GI.1/GII.4 (15/50/500) μg,1-Dose	Geometric Mean Blocking Titer (GMBT50) of Anti-norovirus GII.4 VLP Antibodies as Measured by HBGA Blocking Assay	Day 28	95.2 titer
NOR-107: GI.1/GII.4 (15/50/500) μg,1-Dose	Geometric Mean Blocking Titer (GMBT50) of Anti-norovirus GII.4 VLP Antibodies as Measured by HBGA Blocking Assay	Day 208	333.2 titer
NOR-107: GI.1/GII.4 (15/50/500) μg,1-Dose	Geometric Mean Blocking Titer (GMBT50) of Anti-norovirus GII.4 VLP Antibodies as Measured by HBGA Blocking Assay	Year 3	164.1 titer
NOR-107: GI.1/GII.4 (15/50/500) μg,1-Dose	Geometric Mean Blocking Titer (GMBT50) of Anti-norovirus GII.4 VLP Antibodies as Measured by HBGA Blocking Assay	Baseline	86.3 titer
NOR-107: GI.1/GII.4 (15/50/500) μg,1-Dose	Geometric Mean Blocking Titer (GMBT50) of Anti-norovirus GII.4 VLP Antibodies as Measured by HBGA Blocking Assay	Year 4	131.2 titer
NOR-107: GI.1/GII.4 (15/50/500) μg,1-Dose	Geometric Mean Blocking Titer (GMBT50) of Anti-norovirus GII.4 VLP Antibodies as Measured by HBGA Blocking Assay	Day 56	810.0 titer
NOR-107: GI.1/GII.4 (50/50/500) μg,1-Dose	Geometric Mean Blocking Titer (GMBT50) of Anti-norovirus GII.4 VLP Antibodies as Measured by HBGA Blocking Assay	Baseline	97.1 titer
NOR-107: GI.1/GII.4 (50/50/500) μg,1-Dose	Geometric Mean Blocking Titer (GMBT50) of Anti-norovirus GII.4 VLP Antibodies as Measured by HBGA Blocking Assay	Year 4	101.9 titer
NOR-107: GI.1/GII.4 (50/50/500) μg,1-Dose	Geometric Mean Blocking Titer (GMBT50) of Anti-norovirus GII.4 VLP Antibodies as Measured by HBGA Blocking Assay	Year 5	105.1 titer
NOR-107: GI.1/GII.4 (50/50/500) μg,1-Dose	Geometric Mean Blocking Titer (GMBT50) of Anti-norovirus GII.4 VLP Antibodies as Measured by HBGA Blocking Assay	Day 28	84.1 titer
NOR-107: GI.1/GII.4 (50/50/500) μg,1-Dose	Geometric Mean Blocking Titer (GMBT50) of Anti-norovirus GII.4 VLP Antibodies as Measured by HBGA Blocking Assay	Day 56	328.5 titer
NOR-107: GI.1/GII.4 (50/50/500) μg,1-Dose	Geometric Mean Blocking Titer (GMBT50) of Anti-norovirus GII.4 VLP Antibodies as Measured by HBGA Blocking Assay	Day 208	173.0 titer
NOR-107: GI.1/GII.4 (50/50/500) μg,1-Dose	Geometric Mean Blocking Titer (GMBT50) of Anti-norovirus GII.4 VLP Antibodies as Measured by HBGA Blocking Assay	Year 3	125.3 titer
NOR-107: GI.1/GII.4 (50/150/500) μg,1-Dose	Geometric Mean Blocking Titer (GMBT50) of Anti-norovirus GII.4 VLP Antibodies as Measured by HBGA Blocking Assay	Day 28	129.9 titer
NOR-107: GI.1/GII.4 (50/150/500) μg,1-Dose	Geometric Mean Blocking Titer (GMBT50) of Anti-norovirus GII.4 VLP Antibodies as Measured by HBGA Blocking Assay	Day 56	886.3 titer
NOR-107: GI.1/GII.4 (50/150/500) μg,1-Dose	Geometric Mean Blocking Titer (GMBT50) of Anti-norovirus GII.4 VLP Antibodies as Measured by HBGA Blocking Assay	Day 208	352.9 titer
NOR-107: GI.1/GII.4 (50/150/500) μg,1-Dose	Geometric Mean Blocking Titer (GMBT50) of Anti-norovirus GII.4 VLP Antibodies as Measured by HBGA Blocking Assay	Year 3	167.0 titer
NOR-107: GI.1/GII.4 (50/150/500) μg,1-Dose	Geometric Mean Blocking Titer (GMBT50) of Anti-norovirus GII.4 VLP Antibodies as Measured by HBGA Blocking Assay	Year 5	147.2 titer
NOR-107: GI.1/GII.4 (50/150/500) μg,1-Dose	Geometric Mean Blocking Titer (GMBT50) of Anti-norovirus GII.4 VLP Antibodies as Measured by HBGA Blocking Assay	Baseline	106.1 titer
NOR-107: GI.1/GII.4 (50/150/500) μg,1-Dose	Geometric Mean Blocking Titer (GMBT50) of Anti-norovirus GII.4 VLP Antibodies as Measured by HBGA Blocking Assay	Year 4	113.9 titer
NOR-107: GI.1/GII.4 (15/50/167) μg,1-Dose	Geometric Mean Blocking Titer (GMBT50) of Anti-norovirus GII.4 VLP Antibodies as Measured by HBGA Blocking Assay	Year 5	118.0 titer
NOR-107: GI.1/GII.4 (15/50/167) μg,1-Dose	Geometric Mean Blocking Titer (GMBT50) of Anti-norovirus GII.4 VLP Antibodies as Measured by HBGA Blocking Assay	Day 28	112.4 titer
NOR-107: GI.1/GII.4 (15/50/167) μg,1-Dose	Geometric Mean Blocking Titer (GMBT50) of Anti-norovirus GII.4 VLP Antibodies as Measured by HBGA Blocking Assay	Day 56	746.6 titer
NOR-107: GI.1/GII.4 (15/50/167) μg,1-Dose	Geometric Mean Blocking Titer (GMBT50) of Anti-norovirus GII.4 VLP Antibodies as Measured by HBGA Blocking Assay	Day 208	274.9 titer
NOR-107: GI.1/GII.4 (15/50/167) μg,1-Dose	Geometric Mean Blocking Titer (GMBT50) of Anti-norovirus GII.4 VLP Antibodies as Measured by HBGA Blocking Assay	Year 4	130.1 titer
NOR-107: GI.1/GII.4 (15/50/167) μg,1-Dose	Geometric Mean Blocking Titer (GMBT50) of Anti-norovirus GII.4 VLP Antibodies as Measured by HBGA Blocking Assay	Baseline	124.3 titer
NOR-107: GI.1/GII.4 (15/50/167) μg,1-Dose	Geometric Mean Blocking Titer (GMBT50) of Anti-norovirus GII.4 VLP Antibodies as Measured by HBGA Blocking Assay	Year 3	142.2 titer
NOR-107: GI.1/GII.4 (15/50/500) μg,2-Dose	Geometric Mean Blocking Titer (GMBT50) of Anti-norovirus GII.4 VLP Antibodies as Measured by HBGA Blocking Assay	Day 56	458.4 titer
NOR-107: GI.1/GII.4 (15/50/500) μg,2-Dose	Geometric Mean Blocking Titer (GMBT50) of Anti-norovirus GII.4 VLP Antibodies as Measured by HBGA Blocking Assay	Baseline	65.8 titer
NOR-107: GI.1/GII.4 (15/50/500) μg,2-Dose	Geometric Mean Blocking Titer (GMBT50) of Anti-norovirus GII.4 VLP Antibodies as Measured by HBGA Blocking Assay	Year 3	149.2 titer
NOR-107: GI.1/GII.4 (15/50/500) μg,2-Dose	Geometric Mean Blocking Titer (GMBT50) of Anti-norovirus GII.4 VLP Antibodies as Measured by HBGA Blocking Assay	Day 28	607.7 titer
NOR-107: GI.1/GII.4 (15/50/500) μg,2-Dose	Geometric Mean Blocking Titer (GMBT50) of Anti-norovirus GII.4 VLP Antibodies as Measured by HBGA Blocking Assay	Day 208	277.2 titer
NOR-107: GI.1/GII.4 (15/50/500) μg,2-Dose	Geometric Mean Blocking Titer (GMBT50) of Anti-norovirus GII.4 VLP Antibodies as Measured by HBGA Blocking Assay	Year 5	118.3 titer
NOR-107: GI.1/GII.4 (15/50/500) μg,2-Dose	Geometric Mean Blocking Titer (GMBT50) of Anti-norovirus GII.4 VLP Antibodies as Measured by HBGA Blocking Assay	Year 4	98.1 titer
NOR-107: GI.1/GII.4 (50/150/500) μg,2-Dose	Geometric Mean Blocking Titer (GMBT50) of Anti-norovirus GII.4 VLP Antibodies as Measured by HBGA Blocking Assay	Year 3	144.7 titer
NOR-107: GI.1/GII.4 (50/150/500) μg,2-Dose	Geometric Mean Blocking Titer (GMBT50) of Anti-norovirus GII.4 VLP Antibodies as Measured by HBGA Blocking Assay	Day 208	342.5 titer
NOR-107: GI.1/GII.4 (50/150/500) μg,2-Dose	Geometric Mean Blocking Titer (GMBT50) of Anti-norovirus GII.4 VLP Antibodies as Measured by HBGA Blocking Assay	Year 5	115.7 titer
NOR-107: GI.1/GII.4 (50/150/500) μg,2-Dose	Geometric Mean Blocking Titer (GMBT50) of Anti-norovirus GII.4 VLP Antibodies as Measured by HBGA Blocking Assay	Day 28	668.3 titer
NOR-107: GI.1/GII.4 (50/150/500) μg,2-Dose	Geometric Mean Blocking Titer (GMBT50) of Anti-norovirus GII.4 VLP Antibodies as Measured by HBGA Blocking Assay	Year 4	104.4 titer
NOR-107: GI.1/GII.4 (50/150/500) μg,2-Dose	Geometric Mean Blocking Titer (GMBT50) of Anti-norovirus GII.4 VLP Antibodies as Measured by HBGA Blocking Assay	Day 56	575.5 titer
NOR-107: GI.1/GII.4 (50/150/500) μg,2-Dose	Geometric Mean Blocking Titer (GMBT50) of Anti-norovirus GII.4 VLP Antibodies as Measured by HBGA Blocking Assay	Baseline	97.2 titer
NOR-107: GI.1/GII.4 (15/50/167) μg,2-Dose	Geometric Mean Blocking Titer (GMBT50) of Anti-norovirus GII.4 VLP Antibodies as Measured by HBGA Blocking Assay	Day 208	308.7 titer
NOR-107: GI.1/GII.4 (15/50/167) μg,2-Dose	Geometric Mean Blocking Titer (GMBT50) of Anti-norovirus GII.4 VLP Antibodies as Measured by HBGA Blocking Assay	Year 4	120.3 titer
NOR-107: GI.1/GII.4 (15/50/167) μg,2-Dose	Geometric Mean Blocking Titer (GMBT50) of Anti-norovirus GII.4 VLP Antibodies as Measured by HBGA Blocking Assay	Day 28	893.6 titer
NOR-107: GI.1/GII.4 (15/50/167) μg,2-Dose	Geometric Mean Blocking Titer (GMBT50) of Anti-norovirus GII.4 VLP Antibodies as Measured by HBGA Blocking Assay	Year 3	173.8 titer
NOR-107: GI.1/GII.4 (15/50/167) μg,2-Dose	Geometric Mean Blocking Titer (GMBT50) of Anti-norovirus GII.4 VLP Antibodies as Measured by HBGA Blocking Assay	Year 5	132.0 titer
NOR-107: GI.1/GII.4 (15/50/167) μg,2-Dose	Geometric Mean Blocking Titer (GMBT50) of Anti-norovirus GII.4 VLP Antibodies as Measured by HBGA Blocking Assay	Day 56	594.2 titer
NOR-107: GI.1/GII.4 (15/50/167) μg,2-Dose	Geometric Mean Blocking Titer (GMBT50) of Anti-norovirus GII.4 VLP Antibodies as Measured by HBGA Blocking Assay	Baseline	127.3 titer
NOR-210: GI.1/GII.4 (15/50/500) µg, 1-Dose	Geometric Mean Blocking Titer (GMBT50) of Anti-norovirus GII.4 VLP Antibodies as Measured by HBGA Blocking Assay	Year 3	87.5 titer
NOR-210: GI.1/GII.4 (15/50/500) µg, 1-Dose	Geometric Mean Blocking Titer (GMBT50) of Anti-norovirus GII.4 VLP Antibodies as Measured by HBGA Blocking Assay	Baseline	42.7 titer
NOR-210: GI.1/GII.4 (15/50/500) µg, 1-Dose	Geometric Mean Blocking Titer (GMBT50) of Anti-norovirus GII.4 VLP Antibodies as Measured by HBGA Blocking Assay	Year 5	94.2 titer
NOR-210: GI.1/GII.4 (15/50/500) µg, 1-Dose	Geometric Mean Blocking Titer (GMBT50) of Anti-norovirus GII.4 VLP Antibodies as Measured by HBGA Blocking Assay	Day 29	665.9 titer
NOR-210: GI.1/GII.4 (15/50/500) µg, 1-Dose	Geometric Mean Blocking Titer (GMBT50) of Anti-norovirus GII.4 VLP Antibodies as Measured by HBGA Blocking Assay	Year 2	105.2 titer
NOR-210: GI.1/GII.4 (15/50/500) µg, 1-Dose	Geometric Mean Blocking Titer (GMBT50) of Anti-norovirus GII.4 VLP Antibodies as Measured by HBGA Blocking Assay	Year 4	84.1 titer
NOR-204: GI.1/GII.4 (15/50/500) µg - MPL 15 µg, 1-Dose	Geometric Mean Blocking Titer (GMBT50) of Anti-norovirus GII.4 VLP Antibodies as Measured by HBGA Blocking Assay	Baseline	140.5 titer
NOR-204: GI.1/GII.4 (15/50/500) µg - MPL 15 µg, 1-Dose	Geometric Mean Blocking Titer (GMBT50) of Anti-norovirus GII.4 VLP Antibodies as Measured by HBGA Blocking Assay	Year 5	123.4 titer
NOR-204: GI.1/GII.4 (15/50/500) µg - MPL 15 µg, 1-Dose	Geometric Mean Blocking Titer (GMBT50) of Anti-norovirus GII.4 VLP Antibodies as Measured by HBGA Blocking Assay	Day 29	118.3 titer
NOR-204: GI.1/GII.4 (15/50/500) µg - MPL 15 µg, 1-Dose	Geometric Mean Blocking Titer (GMBT50) of Anti-norovirus GII.4 VLP Antibodies as Measured by HBGA Blocking Assay	Day 36	920.9 titer
NOR-204: GI.1/GII.4 (15/50/500) µg - MPL 15 µg, 1-Dose	Geometric Mean Blocking Titer (GMBT50) of Anti-norovirus GII.4 VLP Antibodies as Measured by HBGA Blocking Assay	Day 57	1133.2 titer
NOR-204: GI.1/GII.4 (15/50/500) µg - MPL 15 µg, 1-Dose	Geometric Mean Blocking Titer (GMBT50) of Anti-norovirus GII.4 VLP Antibodies as Measured by HBGA Blocking Assay	Year 4	116.0 titer
NOR-204: GI.1/GII.4 (15/50/500) µg - MPL 15 µg, 1-Dose	Geometric Mean Blocking Titer (GMBT50) of Anti-norovirus GII.4 VLP Antibodies as Measured by HBGA Blocking Assay	Day 211	417.6 titer
NOR-204: GI.1/GII.4 (15/50/500) µg - MPL 15 µg, 1-Dose	Geometric Mean Blocking Titer (GMBT50) of Anti-norovirus GII.4 VLP Antibodies as Measured by HBGA Blocking Assay	Year 3	172.0 titer
NOR-204: GI.1/GII.4 (15/50/500) µg - MPL 15 µg, 1-Dose	Geometric Mean Blocking Titer (GMBT50) of Anti-norovirus GII.4 VLP Antibodies as Measured by HBGA Blocking Assay	Year 2	223.2 titer
NOR-204: GI.1/GII.4 (15/50/500) µg, 1-Dose (Age: 60-94 Yrs)	Geometric Mean Blocking Titer (GMBT50) of Anti-norovirus GII.4 VLP Antibodies as Measured by HBGA Blocking Assay	Year 3	94.9 titer
NOR-204: GI.1/GII.4 (15/50/500) µg, 1-Dose (Age: 60-94 Yrs)	Geometric Mean Blocking Titer (GMBT50) of Anti-norovirus GII.4 VLP Antibodies as Measured by HBGA Blocking Assay	Day 29	63.5 titer
NOR-204: GI.1/GII.4 (15/50/500) µg, 1-Dose (Age: 60-94 Yrs)	Geometric Mean Blocking Titer (GMBT50) of Anti-norovirus GII.4 VLP Antibodies as Measured by HBGA Blocking Assay	Year 4	80.9 titer
NOR-204: GI.1/GII.4 (15/50/500) µg, 1-Dose (Age: 60-94 Yrs)	Geometric Mean Blocking Titer (GMBT50) of Anti-norovirus GII.4 VLP Antibodies as Measured by HBGA Blocking Assay	Day 211	195.2 titer
NOR-204: GI.1/GII.4 (15/50/500) µg, 1-Dose (Age: 60-94 Yrs)	Geometric Mean Blocking Titer (GMBT50) of Anti-norovirus GII.4 VLP Antibodies as Measured by HBGA Blocking Assay	Year 5	66.8 titer
NOR-204: GI.1/GII.4 (15/50/500) µg, 1-Dose (Age: 60-94 Yrs)	Geometric Mean Blocking Titer (GMBT50) of Anti-norovirus GII.4 VLP Antibodies as Measured by HBGA Blocking Assay	Baseline	71.8 titer
NOR-204: GI.1/GII.4 (15/50/500) µg, 1-Dose (Age: 60-94 Yrs)	Geometric Mean Blocking Titer (GMBT50) of Anti-norovirus GII.4 VLP Antibodies as Measured by HBGA Blocking Assay	Year 2	122.5 titer
NOR-204: GI.1/GII.4 (15/50/500) µg, 1-Dose (Age: 60-94 Yrs)	Geometric Mean Blocking Titer (GMBT50) of Anti-norovirus GII.4 VLP Antibodies as Measured by HBGA Blocking Assay	Day 57	471.8 titer
NOR-204: GI.1/GII.4 (15/50/500) µg, 1-Dose (Age: 60-94 Yrs)	Geometric Mean Blocking Titer (GMBT50) of Anti-norovirus GII.4 VLP Antibodies as Measured by HBGA Blocking Assay	Day 36	518.7 titer
NOR-204: GI.1/GII.4 (15/50/500) µg, 1-Dose (Age: 18-49 Yrs)	Geometric Mean Blocking Titer (GMBT50) of Anti-norovirus GII.4 VLP Antibodies as Measured by HBGA Blocking Assay	Day 57	663.8 titer
NOR-204: GI.1/GII.4 (15/50/500) µg, 1-Dose (Age: 18-49 Yrs)	Geometric Mean Blocking Titer (GMBT50) of Anti-norovirus GII.4 VLP Antibodies as Measured by HBGA Blocking Assay	Year 4	131.1 titer
NOR-204: GI.1/GII.4 (15/50/500) µg, 1-Dose (Age: 18-49 Yrs)	Geometric Mean Blocking Titer (GMBT50) of Anti-norovirus GII.4 VLP Antibodies as Measured by HBGA Blocking Assay	Day 36	1037.4 titer
NOR-204: GI.1/GII.4 (15/50/500) µg, 1-Dose (Age: 18-49 Yrs)	Geometric Mean Blocking Titer (GMBT50) of Anti-norovirus GII.4 VLP Antibodies as Measured by HBGA Blocking Assay	Day 29	83.2 titer
NOR-204: GI.1/GII.4 (15/50/500) µg, 1-Dose (Age: 18-49 Yrs)	Geometric Mean Blocking Titer (GMBT50) of Anti-norovirus GII.4 VLP Antibodies as Measured by HBGA Blocking Assay	Day 211	274.7 titer
NOR-204: GI.1/GII.4 (15/50/500) µg, 1-Dose (Age: 18-49 Yrs)	Geometric Mean Blocking Titer (GMBT50) of Anti-norovirus GII.4 VLP Antibodies as Measured by HBGA Blocking Assay	Year 2	250.5 titer
NOR-204: GI.1/GII.4 (15/50/500) µg, 1-Dose (Age: 18-49 Yrs)	Geometric Mean Blocking Titer (GMBT50) of Anti-norovirus GII.4 VLP Antibodies as Measured by HBGA Blocking Assay	Year 3	133.8 titer
NOR-204: GI.1/GII.4 (15/50/500) µg, 1-Dose (Age: 18-49 Yrs)	Geometric Mean Blocking Titer (GMBT50) of Anti-norovirus GII.4 VLP Antibodies as Measured by HBGA Blocking Assay	Baseline	97.5 titer
NOR-204: GI.1/GII.4 (15/50/500) µg, 1-Dose (Age: 18-49 Yrs)	Geometric Mean Blocking Titer (GMBT50) of Anti-norovirus GII.4 VLP Antibodies as Measured by HBGA Blocking Assay	Year 5	107.4 titer
NOR-204: GI.1/GII.4 (15/50/500) µg - MPL 15 µg, 2-Dose	Geometric Mean Blocking Titer (GMBT50) of Anti-norovirus GII.4 VLP Antibodies as Measured by HBGA Blocking Assay	Day 57	740.2 titer
NOR-204: GI.1/GII.4 (15/50/500) µg - MPL 15 µg, 2-Dose	Geometric Mean Blocking Titer (GMBT50) of Anti-norovirus GII.4 VLP Antibodies as Measured by HBGA Blocking Assay	Year 2	220.9 titer
NOR-204: GI.1/GII.4 (15/50/500) µg - MPL 15 µg, 2-Dose	Geometric Mean Blocking Titer (GMBT50) of Anti-norovirus GII.4 VLP Antibodies as Measured by HBGA Blocking Assay	Year 3	153.3 titer
NOR-204: GI.1/GII.4 (15/50/500) µg - MPL 15 µg, 2-Dose	Geometric Mean Blocking Titer (GMBT50) of Anti-norovirus GII.4 VLP Antibodies as Measured by HBGA Blocking Assay	Year 4	241.9 titer
NOR-204: GI.1/GII.4 (15/50/500) µg - MPL 15 µg, 2-Dose	Geometric Mean Blocking Titer (GMBT50) of Anti-norovirus GII.4 VLP Antibodies as Measured by HBGA Blocking Assay	Day 36	1016.2 titer
NOR-204: GI.1/GII.4 (15/50/500) µg - MPL 15 µg, 2-Dose	Geometric Mean Blocking Titer (GMBT50) of Anti-norovirus GII.4 VLP Antibodies as Measured by HBGA Blocking Assay	Year 5	202.2 titer
NOR-204: GI.1/GII.4 (15/50/500) µg - MPL 15 µg, 2-Dose	Geometric Mean Blocking Titer (GMBT50) of Anti-norovirus GII.4 VLP Antibodies as Measured by HBGA Blocking Assay	Baseline	104.9 titer
NOR-204: GI.1/GII.4 (15/50/500) µg - MPL 15 µg, 2-Dose	Geometric Mean Blocking Titer (GMBT50) of Anti-norovirus GII.4 VLP Antibodies as Measured by HBGA Blocking Assay	Day 211	374.7 titer
NOR-204: GI.1/GII.4 (15/50/500) µg - MPL 15 µg, 2-Dose	Geometric Mean Blocking Titer (GMBT50) of Anti-norovirus GII.4 VLP Antibodies as Measured by HBGA Blocking Assay	Day 29	1134.4 titer
NOR-204: GI.1/GII.4 (15/50/500) µg, 2-Dose	Geometric Mean Blocking Titer (GMBT50) of Anti-norovirus GII.4 VLP Antibodies as Measured by HBGA Blocking Assay	Day 36	766.8 titer
NOR-204: GI.1/GII.4 (15/50/500) µg, 2-Dose	Geometric Mean Blocking Titer (GMBT50) of Anti-norovirus GII.4 VLP Antibodies as Measured by HBGA Blocking Assay	Year 4	136.7 titer
NOR-204: GI.1/GII.4 (15/50/500) µg, 2-Dose	Geometric Mean Blocking Titer (GMBT50) of Anti-norovirus GII.4 VLP Antibodies as Measured by HBGA Blocking Assay	Year 2	243.0 titer
NOR-204: GI.1/GII.4 (15/50/500) µg, 2-Dose	Geometric Mean Blocking Titer (GMBT50) of Anti-norovirus GII.4 VLP Antibodies as Measured by HBGA Blocking Assay	Year 3	162.4 titer
NOR-204: GI.1/GII.4 (15/50/500) µg, 2-Dose	Geometric Mean Blocking Titer (GMBT50) of Anti-norovirus GII.4 VLP Antibodies as Measured by HBGA Blocking Assay	Baseline	111.0 titer
NOR-204: GI.1/GII.4 (15/50/500) µg, 2-Dose	Geometric Mean Blocking Titer (GMBT50) of Anti-norovirus GII.4 VLP Antibodies as Measured by HBGA Blocking Assay	Day 57	589.1 titer
NOR-204: GI.1/GII.4 (15/50/500) µg, 2-Dose	Geometric Mean Blocking Titer (GMBT50) of Anti-norovirus GII.4 VLP Antibodies as Measured by HBGA Blocking Assay	Day 29	824.2 titer
NOR-204: GI.1/GII.4 (15/50/500) µg, 2-Dose	Geometric Mean Blocking Titer (GMBT50) of Anti-norovirus GII.4 VLP Antibodies as Measured by HBGA Blocking Assay	Year 5	187.3 titer
NOR-204: GI.1/GII.4 (15/50/500) µg, 2-Dose	Geometric Mean Blocking Titer (GMBT50) of Anti-norovirus GII.4 VLP Antibodies as Measured by HBGA Blocking Assay	Day 211	265.3 titer

Primary

Geometric Mean Blocking Titers 50 Percent (%) (GMBT50) of Anti-norovirus GI.1 VLP Antibodies as Measured by Histo-Blood Group Antigen HBGA Blocking Assay

GMBT50 of anti-norovirus GI. VLP antibody titers as measured by the histo-blood group antigen (HBGA) blocking assay. Data reported for up to Year 5 was collected at Baseline (NOR-107, NOR-210, NOR-204) , at Days 28 (NOR-107), 29 (NOR-204 and NOR-210), Day 36 (NOR-204), Day 56 (NOR-107) and Day 57 (NOR-204), Day 208 (NOR-107) and Day 211 (NOR-204), Year 2 (NOR-204 and NOR-210) Years 3, 4 and 5 (NOR-107, NOR-210, NOR-204)

Time frame: Baseline up to Year 2 post-primary vaccination of initial study NOR-107, NOR-210 NOR-204 and up to Year 5 of this extension study

Population: Per Protocol Set (PPS) included all participants in the FAS who had no major or critical protocol violations that potentially confound the primary endpoint. Number analyzed is the number of participants with data available for analysis at specific timepoints.

Arm	Measure	Group	Value (GEOMETRIC_MEAN)
NOR-107: GI.1/GII.4 (15/15/500) μg- MPL 50 μg,1-Dose	Geometric Mean Blocking Titers 50 Percent (%) (GMBT50) of Anti-norovirus GI.1 VLP Antibodies as Measured by Histo-Blood Group Antigen HBGA Blocking Assay	Year 5	71.0 titer
NOR-107: GI.1/GII.4 (15/15/500) μg- MPL 50 μg,1-Dose	Geometric Mean Blocking Titers 50 Percent (%) (GMBT50) of Anti-norovirus GI.1 VLP Antibodies as Measured by Histo-Blood Group Antigen HBGA Blocking Assay	Year 3	79.6 titer
NOR-107: GI.1/GII.4 (15/15/500) μg- MPL 50 μg,1-Dose	Geometric Mean Blocking Titers 50 Percent (%) (GMBT50) of Anti-norovirus GI.1 VLP Antibodies as Measured by Histo-Blood Group Antigen HBGA Blocking Assay	Day 56	309.7 titer
NOR-107: GI.1/GII.4 (15/15/500) μg- MPL 50 μg,1-Dose	Geometric Mean Blocking Titers 50 Percent (%) (GMBT50) of Anti-norovirus GI.1 VLP Antibodies as Measured by Histo-Blood Group Antigen HBGA Blocking Assay	Day 208	143.5 titer
NOR-107: GI.1/GII.4 (15/15/500) μg- MPL 50 μg,1-Dose	Geometric Mean Blocking Titers 50 Percent (%) (GMBT50) of Anti-norovirus GI.1 VLP Antibodies as Measured by Histo-Blood Group Antigen HBGA Blocking Assay	Days 28	27.7 titer
NOR-107: GI.1/GII.4 (15/15/500) μg- MPL 50 μg,1-Dose	Geometric Mean Blocking Titers 50 Percent (%) (GMBT50) of Anti-norovirus GI.1 VLP Antibodies as Measured by Histo-Blood Group Antigen HBGA Blocking Assay	Year 4	70.5 titer
NOR-107: GI.1/GII.4 (15/15/500) μg- MPL 50 μg,1-Dose	Geometric Mean Blocking Titers 50 Percent (%) (GMBT50) of Anti-norovirus GI.1 VLP Antibodies as Measured by Histo-Blood Group Antigen HBGA Blocking Assay	Baseline	27.4 titer
NOR-107: GI.1/GII.4 (15/50/500) μg- MPL 50 μg,1-Dose	Geometric Mean Blocking Titers 50 Percent (%) (GMBT50) of Anti-norovirus GI.1 VLP Antibodies as Measured by Histo-Blood Group Antigen HBGA Blocking Assay	Day 208	109.1 titer
NOR-107: GI.1/GII.4 (15/50/500) μg- MPL 50 μg,1-Dose	Geometric Mean Blocking Titers 50 Percent (%) (GMBT50) of Anti-norovirus GI.1 VLP Antibodies as Measured by Histo-Blood Group Antigen HBGA Blocking Assay	Year 5	42.5 titer
NOR-107: GI.1/GII.4 (15/50/500) μg- MPL 50 μg,1-Dose	Geometric Mean Blocking Titers 50 Percent (%) (GMBT50) of Anti-norovirus GI.1 VLP Antibodies as Measured by Histo-Blood Group Antigen HBGA Blocking Assay	Baseline	18.3 titer
NOR-107: GI.1/GII.4 (15/50/500) μg- MPL 50 μg,1-Dose	Geometric Mean Blocking Titers 50 Percent (%) (GMBT50) of Anti-norovirus GI.1 VLP Antibodies as Measured by Histo-Blood Group Antigen HBGA Blocking Assay	Year 3	53.7 titer
NOR-107: GI.1/GII.4 (15/50/500) μg- MPL 50 μg,1-Dose	Geometric Mean Blocking Titers 50 Percent (%) (GMBT50) of Anti-norovirus GI.1 VLP Antibodies as Measured by Histo-Blood Group Antigen HBGA Blocking Assay	Year 4	47.5 titer
NOR-107: GI.1/GII.4 (15/50/500) μg- MPL 50 μg,1-Dose	Geometric Mean Blocking Titers 50 Percent (%) (GMBT50) of Anti-norovirus GI.1 VLP Antibodies as Measured by Histo-Blood Group Antigen HBGA Blocking Assay	Day 56	256.9 titer
NOR-107: GI.1/GII.4 (15/50/500) μg- MPL 50 μg,1-Dose	Geometric Mean Blocking Titers 50 Percent (%) (GMBT50) of Anti-norovirus GI.1 VLP Antibodies as Measured by Histo-Blood Group Antigen HBGA Blocking Assay	Days 28	18.1 titer
NOR-107: GI.1/GII.4 (50/50/500) μg- MPL 50 μg,1-Dose	Geometric Mean Blocking Titers 50 Percent (%) (GMBT50) of Anti-norovirus GI.1 VLP Antibodies as Measured by Histo-Blood Group Antigen HBGA Blocking Assay	Year 4	68.6 titer
NOR-107: GI.1/GII.4 (50/50/500) μg- MPL 50 μg,1-Dose	Geometric Mean Blocking Titers 50 Percent (%) (GMBT50) of Anti-norovirus GI.1 VLP Antibodies as Measured by Histo-Blood Group Antigen HBGA Blocking Assay	Day 56	380.9 titer
NOR-107: GI.1/GII.4 (50/50/500) μg- MPL 50 μg,1-Dose	Geometric Mean Blocking Titers 50 Percent (%) (GMBT50) of Anti-norovirus GI.1 VLP Antibodies as Measured by Histo-Blood Group Antigen HBGA Blocking Assay	Day 208	154.8 titer
NOR-107: GI.1/GII.4 (50/50/500) μg- MPL 50 μg,1-Dose	Geometric Mean Blocking Titers 50 Percent (%) (GMBT50) of Anti-norovirus GI.1 VLP Antibodies as Measured by Histo-Blood Group Antigen HBGA Blocking Assay	Baseline	26.3 titer
NOR-107: GI.1/GII.4 (50/50/500) μg- MPL 50 μg,1-Dose	Geometric Mean Blocking Titers 50 Percent (%) (GMBT50) of Anti-norovirus GI.1 VLP Antibodies as Measured by Histo-Blood Group Antigen HBGA Blocking Assay	Year 3	77.2 titer
NOR-107: GI.1/GII.4 (50/50/500) μg- MPL 50 μg,1-Dose	Geometric Mean Blocking Titers 50 Percent (%) (GMBT50) of Anti-norovirus GI.1 VLP Antibodies as Measured by Histo-Blood Group Antigen HBGA Blocking Assay	Year 5	80.5 titer
NOR-107: GI.1/GII.4 (50/50/500) μg- MPL 50 μg,1-Dose	Geometric Mean Blocking Titers 50 Percent (%) (GMBT50) of Anti-norovirus GI.1 VLP Antibodies as Measured by Histo-Blood Group Antigen HBGA Blocking Assay	Days 28	23.8 titer
NOR-107: GI.1/GII.4 (15/15/500) μg- MPL 15 μg,1-Dose	Geometric Mean Blocking Titers 50 Percent (%) (GMBT50) of Anti-norovirus GI.1 VLP Antibodies as Measured by Histo-Blood Group Antigen HBGA Blocking Assay	Day 208	125.6 titer
NOR-107: GI.1/GII.4 (15/15/500) μg- MPL 15 μg,1-Dose	Geometric Mean Blocking Titers 50 Percent (%) (GMBT50) of Anti-norovirus GI.1 VLP Antibodies as Measured by Histo-Blood Group Antigen HBGA Blocking Assay	Baseline	24.6 titer
NOR-107: GI.1/GII.4 (15/15/500) μg- MPL 15 μg,1-Dose	Geometric Mean Blocking Titers 50 Percent (%) (GMBT50) of Anti-norovirus GI.1 VLP Antibodies as Measured by Histo-Blood Group Antigen HBGA Blocking Assay	Year 3	72.4 titer
NOR-107: GI.1/GII.4 (15/15/500) μg- MPL 15 μg,1-Dose	Geometric Mean Blocking Titers 50 Percent (%) (GMBT50) of Anti-norovirus GI.1 VLP Antibodies as Measured by Histo-Blood Group Antigen HBGA Blocking Assay	Day 56	255.4 titer
NOR-107: GI.1/GII.4 (15/15/500) μg- MPL 15 μg,1-Dose	Geometric Mean Blocking Titers 50 Percent (%) (GMBT50) of Anti-norovirus GI.1 VLP Antibodies as Measured by Histo-Blood Group Antigen HBGA Blocking Assay	Year 4	54.0 titer
NOR-107: GI.1/GII.4 (15/15/500) μg- MPL 15 μg,1-Dose	Geometric Mean Blocking Titers 50 Percent (%) (GMBT50) of Anti-norovirus GI.1 VLP Antibodies as Measured by Histo-Blood Group Antigen HBGA Blocking Assay	Year 5	54.4 titer
NOR-107: GI.1/GII.4 (15/15/500) μg- MPL 15 μg,1-Dose	Geometric Mean Blocking Titers 50 Percent (%) (GMBT50) of Anti-norovirus GI.1 VLP Antibodies as Measured by Histo-Blood Group Antigen HBGA Blocking Assay	Days 28	24.0 titer
NOR-107: GI.1/GII.4 (15/50/500) μg- MPL 15 μg,1-Dose	Geometric Mean Blocking Titers 50 Percent (%) (GMBT50) of Anti-norovirus GI.1 VLP Antibodies as Measured by Histo-Blood Group Antigen HBGA Blocking Assay	Day 56	252.9 titer
NOR-107: GI.1/GII.4 (15/50/500) μg- MPL 15 μg,1-Dose	Geometric Mean Blocking Titers 50 Percent (%) (GMBT50) of Anti-norovirus GI.1 VLP Antibodies as Measured by Histo-Blood Group Antigen HBGA Blocking Assay	Year 5	50.5 titer
NOR-107: GI.1/GII.4 (15/50/500) μg- MPL 15 μg,1-Dose	Geometric Mean Blocking Titers 50 Percent (%) (GMBT50) of Anti-norovirus GI.1 VLP Antibodies as Measured by Histo-Blood Group Antigen HBGA Blocking Assay	Baseline	19.0 titer
NOR-107: GI.1/GII.4 (15/50/500) μg- MPL 15 μg,1-Dose	Geometric Mean Blocking Titers 50 Percent (%) (GMBT50) of Anti-norovirus GI.1 VLP Antibodies as Measured by Histo-Blood Group Antigen HBGA Blocking Assay	Year 4	54.8 titer
NOR-107: GI.1/GII.4 (15/50/500) μg- MPL 15 μg,1-Dose	Geometric Mean Blocking Titers 50 Percent (%) (GMBT50) of Anti-norovirus GI.1 VLP Antibodies as Measured by Histo-Blood Group Antigen HBGA Blocking Assay	Days 28	17.4 titer
NOR-107: GI.1/GII.4 (15/50/500) μg- MPL 15 μg,1-Dose	Geometric Mean Blocking Titers 50 Percent (%) (GMBT50) of Anti-norovirus GI.1 VLP Antibodies as Measured by Histo-Blood Group Antigen HBGA Blocking Assay	Year 3	51.5 titer
NOR-107: GI.1/GII.4 (15/50/500) μg- MPL 15 μg,1-Dose	Geometric Mean Blocking Titers 50 Percent (%) (GMBT50) of Anti-norovirus GI.1 VLP Antibodies as Measured by Histo-Blood Group Antigen HBGA Blocking Assay	Day 208	86.4 titer
NOR-107: GI.1/GII.4 (50/50/500) μg- MPL 15 μg,1-Dose	Geometric Mean Blocking Titers 50 Percent (%) (GMBT50) of Anti-norovirus GI.1 VLP Antibodies as Measured by Histo-Blood Group Antigen HBGA Blocking Assay	Baseline	23.9 titer
NOR-107: GI.1/GII.4 (50/50/500) μg- MPL 15 μg,1-Dose	Geometric Mean Blocking Titers 50 Percent (%) (GMBT50) of Anti-norovirus GI.1 VLP Antibodies as Measured by Histo-Blood Group Antigen HBGA Blocking Assay	Year 5	54.5 titer
NOR-107: GI.1/GII.4 (50/50/500) μg- MPL 15 μg,1-Dose	Geometric Mean Blocking Titers 50 Percent (%) (GMBT50) of Anti-norovirus GI.1 VLP Antibodies as Measured by Histo-Blood Group Antigen HBGA Blocking Assay	Year 4	49.3 titer
NOR-107: GI.1/GII.4 (50/50/500) μg- MPL 15 μg,1-Dose	Geometric Mean Blocking Titers 50 Percent (%) (GMBT50) of Anti-norovirus GI.1 VLP Antibodies as Measured by Histo-Blood Group Antigen HBGA Blocking Assay	Days 28	21.9 titer
NOR-107: GI.1/GII.4 (50/50/500) μg- MPL 15 μg,1-Dose	Geometric Mean Blocking Titers 50 Percent (%) (GMBT50) of Anti-norovirus GI.1 VLP Antibodies as Measured by Histo-Blood Group Antigen HBGA Blocking Assay	Year 3	55.5 titer
NOR-107: GI.1/GII.4 (50/50/500) μg- MPL 15 μg,1-Dose	Geometric Mean Blocking Titers 50 Percent (%) (GMBT50) of Anti-norovirus GI.1 VLP Antibodies as Measured by Histo-Blood Group Antigen HBGA Blocking Assay	Day 208	137.9 titer
NOR-107: GI.1/GII.4 (50/50/500) μg- MPL 15 μg,1-Dose	Geometric Mean Blocking Titers 50 Percent (%) (GMBT50) of Anti-norovirus GI.1 VLP Antibodies as Measured by Histo-Blood Group Antigen HBGA Blocking Assay	Day 56	329.2 titer
NOR-107: GI.1/GII.4 (15/15/500) μg,1-Dose	Geometric Mean Blocking Titers 50 Percent (%) (GMBT50) of Anti-norovirus GI.1 VLP Antibodies as Measured by Histo-Blood Group Antigen HBGA Blocking Assay	Year 4	84.9 titer
NOR-107: GI.1/GII.4 (15/15/500) μg,1-Dose	Geometric Mean Blocking Titers 50 Percent (%) (GMBT50) of Anti-norovirus GI.1 VLP Antibodies as Measured by Histo-Blood Group Antigen HBGA Blocking Assay	Year 3	98.0 titer
NOR-107: GI.1/GII.4 (15/15/500) μg,1-Dose	Geometric Mean Blocking Titers 50 Percent (%) (GMBT50) of Anti-norovirus GI.1 VLP Antibodies as Measured by Histo-Blood Group Antigen HBGA Blocking Assay	Year 5	77.2 titer
NOR-107: GI.1/GII.4 (15/15/500) μg,1-Dose	Geometric Mean Blocking Titers 50 Percent (%) (GMBT50) of Anti-norovirus GI.1 VLP Antibodies as Measured by Histo-Blood Group Antigen HBGA Blocking Assay	Baseline	35.1 titer
NOR-107: GI.1/GII.4 (15/15/500) μg,1-Dose	Geometric Mean Blocking Titers 50 Percent (%) (GMBT50) of Anti-norovirus GI.1 VLP Antibodies as Measured by Histo-Blood Group Antigen HBGA Blocking Assay	Day 56	369.5 titer
NOR-107: GI.1/GII.4 (15/15/500) μg,1-Dose	Geometric Mean Blocking Titers 50 Percent (%) (GMBT50) of Anti-norovirus GI.1 VLP Antibodies as Measured by Histo-Blood Group Antigen HBGA Blocking Assay	Day 208	168.9 titer
NOR-107: GI.1/GII.4 (15/15/500) μg,1-Dose	Geometric Mean Blocking Titers 50 Percent (%) (GMBT50) of Anti-norovirus GI.1 VLP Antibodies as Measured by Histo-Blood Group Antigen HBGA Blocking Assay	Days 28	29.9 titer
NOR-107: GI.1/GII.4 (15/50/500) μg,1-Dose	Geometric Mean Blocking Titers 50 Percent (%) (GMBT50) of Anti-norovirus GI.1 VLP Antibodies as Measured by Histo-Blood Group Antigen HBGA Blocking Assay	Day 208	175.4 titer
NOR-107: GI.1/GII.4 (15/50/500) μg,1-Dose	Geometric Mean Blocking Titers 50 Percent (%) (GMBT50) of Anti-norovirus GI.1 VLP Antibodies as Measured by Histo-Blood Group Antigen HBGA Blocking Assay	Year 4	67.3 titer
NOR-107: GI.1/GII.4 (15/50/500) μg,1-Dose	Geometric Mean Blocking Titers 50 Percent (%) (GMBT50) of Anti-norovirus GI.1 VLP Antibodies as Measured by Histo-Blood Group Antigen HBGA Blocking Assay	Year 5	82.2 titer
NOR-107: GI.1/GII.4 (15/50/500) μg,1-Dose	Geometric Mean Blocking Titers 50 Percent (%) (GMBT50) of Anti-norovirus GI.1 VLP Antibodies as Measured by Histo-Blood Group Antigen HBGA Blocking Assay	Baseline	24.3 titer
NOR-107: GI.1/GII.4 (15/50/500) μg,1-Dose	Geometric Mean Blocking Titers 50 Percent (%) (GMBT50) of Anti-norovirus GI.1 VLP Antibodies as Measured by Histo-Blood Group Antigen HBGA Blocking Assay	Days 28	24.9 titer
NOR-107: GI.1/GII.4 (15/50/500) μg,1-Dose	Geometric Mean Blocking Titers 50 Percent (%) (GMBT50) of Anti-norovirus GI.1 VLP Antibodies as Measured by Histo-Blood Group Antigen HBGA Blocking Assay	Year 3	90.2 titer
NOR-107: GI.1/GII.4 (15/50/500) μg,1-Dose	Geometric Mean Blocking Titers 50 Percent (%) (GMBT50) of Anti-norovirus GI.1 VLP Antibodies as Measured by Histo-Blood Group Antigen HBGA Blocking Assay	Day 56	350.4 titer
NOR-107: GI.1/GII.4 (50/50/500) μg,1-Dose	Geometric Mean Blocking Titers 50 Percent (%) (GMBT50) of Anti-norovirus GI.1 VLP Antibodies as Measured by Histo-Blood Group Antigen HBGA Blocking Assay	Days 28	27.3 titer
NOR-107: GI.1/GII.4 (50/50/500) μg,1-Dose	Geometric Mean Blocking Titers 50 Percent (%) (GMBT50) of Anti-norovirus GI.1 VLP Antibodies as Measured by Histo-Blood Group Antigen HBGA Blocking Assay	Year 3	102.2 titer
NOR-107: GI.1/GII.4 (50/50/500) μg,1-Dose	Geometric Mean Blocking Titers 50 Percent (%) (GMBT50) of Anti-norovirus GI.1 VLP Antibodies as Measured by Histo-Blood Group Antigen HBGA Blocking Assay	Baseline	26.1 titer
NOR-107: GI.1/GII.4 (50/50/500) μg,1-Dose	Geometric Mean Blocking Titers 50 Percent (%) (GMBT50) of Anti-norovirus GI.1 VLP Antibodies as Measured by Histo-Blood Group Antigen HBGA Blocking Assay	Day 56	527.0 titer
NOR-107: GI.1/GII.4 (50/50/500) μg,1-Dose	Geometric Mean Blocking Titers 50 Percent (%) (GMBT50) of Anti-norovirus GI.1 VLP Antibodies as Measured by Histo-Blood Group Antigen HBGA Blocking Assay	Day 208	214.1 titer
NOR-107: GI.1/GII.4 (50/50/500) μg,1-Dose	Geometric Mean Blocking Titers 50 Percent (%) (GMBT50) of Anti-norovirus GI.1 VLP Antibodies as Measured by Histo-Blood Group Antigen HBGA Blocking Assay	Year 4	78.2 titer
NOR-107: GI.1/GII.4 (50/50/500) μg,1-Dose	Geometric Mean Blocking Titers 50 Percent (%) (GMBT50) of Anti-norovirus GI.1 VLP Antibodies as Measured by Histo-Blood Group Antigen HBGA Blocking Assay	Year 5	80.9 titer
NOR-107: GI.1/GII.4 (50/150/500) μg,1-Dose	Geometric Mean Blocking Titers 50 Percent (%) (GMBT50) of Anti-norovirus GI.1 VLP Antibodies as Measured by Histo-Blood Group Antigen HBGA Blocking Assay	Year 5	54.1 titer
NOR-107: GI.1/GII.4 (50/150/500) μg,1-Dose	Geometric Mean Blocking Titers 50 Percent (%) (GMBT50) of Anti-norovirus GI.1 VLP Antibodies as Measured by Histo-Blood Group Antigen HBGA Blocking Assay	Days 28	25.8 titer
NOR-107: GI.1/GII.4 (50/150/500) μg,1-Dose	Geometric Mean Blocking Titers 50 Percent (%) (GMBT50) of Anti-norovirus GI.1 VLP Antibodies as Measured by Histo-Blood Group Antigen HBGA Blocking Assay	Day 56	274.3 titer
NOR-107: GI.1/GII.4 (50/150/500) μg,1-Dose	Geometric Mean Blocking Titers 50 Percent (%) (GMBT50) of Anti-norovirus GI.1 VLP Antibodies as Measured by Histo-Blood Group Antigen HBGA Blocking Assay	Year 4	45.5 titer
NOR-107: GI.1/GII.4 (50/150/500) μg,1-Dose	Geometric Mean Blocking Titers 50 Percent (%) (GMBT50) of Anti-norovirus GI.1 VLP Antibodies as Measured by Histo-Blood Group Antigen HBGA Blocking Assay	Baseline	23.9 titer
NOR-107: GI.1/GII.4 (50/150/500) μg,1-Dose	Geometric Mean Blocking Titers 50 Percent (%) (GMBT50) of Anti-norovirus GI.1 VLP Antibodies as Measured by Histo-Blood Group Antigen HBGA Blocking Assay	Year 3	61.8 titer
NOR-107: GI.1/GII.4 (50/150/500) μg,1-Dose	Geometric Mean Blocking Titers 50 Percent (%) (GMBT50) of Anti-norovirus GI.1 VLP Antibodies as Measured by Histo-Blood Group Antigen HBGA Blocking Assay	Day 208	125.3 titer
NOR-107: GI.1/GII.4 (15/50/167) μg,1-Dose	Geometric Mean Blocking Titers 50 Percent (%) (GMBT50) of Anti-norovirus GI.1 VLP Antibodies as Measured by Histo-Blood Group Antigen HBGA Blocking Assay	Year 5	62.0 titer
NOR-107: GI.1/GII.4 (15/50/167) μg,1-Dose	Geometric Mean Blocking Titers 50 Percent (%) (GMBT50) of Anti-norovirus GI.1 VLP Antibodies as Measured by Histo-Blood Group Antigen HBGA Blocking Assay	Day 208	115.3 titer
NOR-107: GI.1/GII.4 (15/50/167) μg,1-Dose	Geometric Mean Blocking Titers 50 Percent (%) (GMBT50) of Anti-norovirus GI.1 VLP Antibodies as Measured by Histo-Blood Group Antigen HBGA Blocking Assay	Year 4	61.2 titer
NOR-107: GI.1/GII.4 (15/50/167) μg,1-Dose	Geometric Mean Blocking Titers 50 Percent (%) (GMBT50) of Anti-norovirus GI.1 VLP Antibodies as Measured by Histo-Blood Group Antigen HBGA Blocking Assay	Baseline	33.4 titer
NOR-107: GI.1/GII.4 (15/50/167) μg,1-Dose	Geometric Mean Blocking Titers 50 Percent (%) (GMBT50) of Anti-norovirus GI.1 VLP Antibodies as Measured by Histo-Blood Group Antigen HBGA Blocking Assay	Days 28	34.9 titer
NOR-107: GI.1/GII.4 (15/50/167) μg,1-Dose	Geometric Mean Blocking Titers 50 Percent (%) (GMBT50) of Anti-norovirus GI.1 VLP Antibodies as Measured by Histo-Blood Group Antigen HBGA Blocking Assay	Day 56	315.8 titer
NOR-107: GI.1/GII.4 (15/50/167) μg,1-Dose	Geometric Mean Blocking Titers 50 Percent (%) (GMBT50) of Anti-norovirus GI.1 VLP Antibodies as Measured by Histo-Blood Group Antigen HBGA Blocking Assay	Year 3	67.2 titer
NOR-107: GI.1/GII.4 (15/50/500) μg,2-Dose	Geometric Mean Blocking Titers 50 Percent (%) (GMBT50) of Anti-norovirus GI.1 VLP Antibodies as Measured by Histo-Blood Group Antigen HBGA Blocking Assay	Day 56	435.9 titer
NOR-107: GI.1/GII.4 (15/50/500) μg,2-Dose	Geometric Mean Blocking Titers 50 Percent (%) (GMBT50) of Anti-norovirus GI.1 VLP Antibodies as Measured by Histo-Blood Group Antigen HBGA Blocking Assay	Year 4	85.8 titer
NOR-107: GI.1/GII.4 (15/50/500) μg,2-Dose	Geometric Mean Blocking Titers 50 Percent (%) (GMBT50) of Anti-norovirus GI.1 VLP Antibodies as Measured by Histo-Blood Group Antigen HBGA Blocking Assay	Year 3	90.5 titer
NOR-107: GI.1/GII.4 (15/50/500) μg,2-Dose	Geometric Mean Blocking Titers 50 Percent (%) (GMBT50) of Anti-norovirus GI.1 VLP Antibodies as Measured by Histo-Blood Group Antigen HBGA Blocking Assay	Year 5	82.1 titer
NOR-107: GI.1/GII.4 (15/50/500) μg,2-Dose	Geometric Mean Blocking Titers 50 Percent (%) (GMBT50) of Anti-norovirus GI.1 VLP Antibodies as Measured by Histo-Blood Group Antigen HBGA Blocking Assay	Day 208	208.7 titer
NOR-107: GI.1/GII.4 (15/50/500) μg,2-Dose	Geometric Mean Blocking Titers 50 Percent (%) (GMBT50) of Anti-norovirus GI.1 VLP Antibodies as Measured by Histo-Blood Group Antigen HBGA Blocking Assay	Days 28	382.6 titer
NOR-107: GI.1/GII.4 (15/50/500) μg,2-Dose	Geometric Mean Blocking Titers 50 Percent (%) (GMBT50) of Anti-norovirus GI.1 VLP Antibodies as Measured by Histo-Blood Group Antigen HBGA Blocking Assay	Baseline	23.1 titer
NOR-107: GI.1/GII.4 (50/150/500) μg,2-Dose	Geometric Mean Blocking Titers 50 Percent (%) (GMBT50) of Anti-norovirus GI.1 VLP Antibodies as Measured by Histo-Blood Group Antigen HBGA Blocking Assay	Year 4	65.1 titer
NOR-107: GI.1/GII.4 (50/150/500) μg,2-Dose	Geometric Mean Blocking Titers 50 Percent (%) (GMBT50) of Anti-norovirus GI.1 VLP Antibodies as Measured by Histo-Blood Group Antigen HBGA Blocking Assay	Year 5	69.1 titer
NOR-107: GI.1/GII.4 (50/150/500) μg,2-Dose	Geometric Mean Blocking Titers 50 Percent (%) (GMBT50) of Anti-norovirus GI.1 VLP Antibodies as Measured by Histo-Blood Group Antigen HBGA Blocking Assay	Day 208	201.5 titer
NOR-107: GI.1/GII.4 (50/150/500) μg,2-Dose	Geometric Mean Blocking Titers 50 Percent (%) (GMBT50) of Anti-norovirus GI.1 VLP Antibodies as Measured by Histo-Blood Group Antigen HBGA Blocking Assay	Day 56	427.6 titer
NOR-107: GI.1/GII.4 (50/150/500) μg,2-Dose	Geometric Mean Blocking Titers 50 Percent (%) (GMBT50) of Anti-norovirus GI.1 VLP Antibodies as Measured by Histo-Blood Group Antigen HBGA Blocking Assay	Baseline	22.9 titer
NOR-107: GI.1/GII.4 (50/150/500) μg,2-Dose	Geometric Mean Blocking Titers 50 Percent (%) (GMBT50) of Anti-norovirus GI.1 VLP Antibodies as Measured by Histo-Blood Group Antigen HBGA Blocking Assay	Days 28	338.0 titer
NOR-107: GI.1/GII.4 (50/150/500) μg,2-Dose	Geometric Mean Blocking Titers 50 Percent (%) (GMBT50) of Anti-norovirus GI.1 VLP Antibodies as Measured by Histo-Blood Group Antigen HBGA Blocking Assay	Year 3	84.9 titer
NOR-107: GI.1/GII.4 (15/50/167) μg,2-Dose	Geometric Mean Blocking Titers 50 Percent (%) (GMBT50) of Anti-norovirus GI.1 VLP Antibodies as Measured by Histo-Blood Group Antigen HBGA Blocking Assay	Year 3	85.7 titer
NOR-107: GI.1/GII.4 (15/50/167) μg,2-Dose	Geometric Mean Blocking Titers 50 Percent (%) (GMBT50) of Anti-norovirus GI.1 VLP Antibodies as Measured by Histo-Blood Group Antigen HBGA Blocking Assay	Day 208	185.6 titer
NOR-107: GI.1/GII.4 (15/50/167) μg,2-Dose	Geometric Mean Blocking Titers 50 Percent (%) (GMBT50) of Anti-norovirus GI.1 VLP Antibodies as Measured by Histo-Blood Group Antigen HBGA Blocking Assay	Day 56	377.4 titer
NOR-107: GI.1/GII.4 (15/50/167) μg,2-Dose	Geometric Mean Blocking Titers 50 Percent (%) (GMBT50) of Anti-norovirus GI.1 VLP Antibodies as Measured by Histo-Blood Group Antigen HBGA Blocking Assay	Baseline	21.3 titer
NOR-107: GI.1/GII.4 (15/50/167) μg,2-Dose	Geometric Mean Blocking Titers 50 Percent (%) (GMBT50) of Anti-norovirus GI.1 VLP Antibodies as Measured by Histo-Blood Group Antigen HBGA Blocking Assay	Year 4	67.2 titer
NOR-107: GI.1/GII.4 (15/50/167) μg,2-Dose	Geometric Mean Blocking Titers 50 Percent (%) (GMBT50) of Anti-norovirus GI.1 VLP Antibodies as Measured by Histo-Blood Group Antigen HBGA Blocking Assay	Days 28	449.4 titer
NOR-107: GI.1/GII.4 (15/50/167) μg,2-Dose	Geometric Mean Blocking Titers 50 Percent (%) (GMBT50) of Anti-norovirus GI.1 VLP Antibodies as Measured by Histo-Blood Group Antigen HBGA Blocking Assay	Year 5	74.9 titer
NOR-210: GI.1/GII.4 (15/50/500) µg, 1-Dose	Geometric Mean Blocking Titers 50 Percent (%) (GMBT50) of Anti-norovirus GI.1 VLP Antibodies as Measured by Histo-Blood Group Antigen HBGA Blocking Assay	Year 5	52.8 titer
NOR-210: GI.1/GII.4 (15/50/500) µg, 1-Dose	Geometric Mean Blocking Titers 50 Percent (%) (GMBT50) of Anti-norovirus GI.1 VLP Antibodies as Measured by Histo-Blood Group Antigen HBGA Blocking Assay	Days 29	212.5 titer
NOR-210: GI.1/GII.4 (15/50/500) µg, 1-Dose	Geometric Mean Blocking Titers 50 Percent (%) (GMBT50) of Anti-norovirus GI.1 VLP Antibodies as Measured by Histo-Blood Group Antigen HBGA Blocking Assay	Baseline	19.0 titer
NOR-210: GI.1/GII.4 (15/50/500) µg, 1-Dose	Geometric Mean Blocking Titers 50 Percent (%) (GMBT50) of Anti-norovirus GI.1 VLP Antibodies as Measured by Histo-Blood Group Antigen HBGA Blocking Assay	Year 3	48.2 titer
NOR-210: GI.1/GII.4 (15/50/500) µg, 1-Dose	Geometric Mean Blocking Titers 50 Percent (%) (GMBT50) of Anti-norovirus GI.1 VLP Antibodies as Measured by Histo-Blood Group Antigen HBGA Blocking Assay	Year 2	48.8 titer
NOR-210: GI.1/GII.4 (15/50/500) µg, 1-Dose	Geometric Mean Blocking Titers 50 Percent (%) (GMBT50) of Anti-norovirus GI.1 VLP Antibodies as Measured by Histo-Blood Group Antigen HBGA Blocking Assay	Year 4	63.8 titer
NOR-204: GI.1/GII.4 (15/50/500) µg - MPL 15 µg, 1-Dose	Geometric Mean Blocking Titers 50 Percent (%) (GMBT50) of Anti-norovirus GI.1 VLP Antibodies as Measured by Histo-Blood Group Antigen HBGA Blocking Assay	Day 211	115.9 titer
NOR-204: GI.1/GII.4 (15/50/500) µg - MPL 15 µg, 1-Dose	Geometric Mean Blocking Titers 50 Percent (%) (GMBT50) of Anti-norovirus GI.1 VLP Antibodies as Measured by Histo-Blood Group Antigen HBGA Blocking Assay	Year 2	46.3 titer
NOR-204: GI.1/GII.4 (15/50/500) µg - MPL 15 µg, 1-Dose	Geometric Mean Blocking Titers 50 Percent (%) (GMBT50) of Anti-norovirus GI.1 VLP Antibodies as Measured by Histo-Blood Group Antigen HBGA Blocking Assay	Year 3	48.8 titer
NOR-204: GI.1/GII.4 (15/50/500) µg - MPL 15 µg, 1-Dose	Geometric Mean Blocking Titers 50 Percent (%) (GMBT50) of Anti-norovirus GI.1 VLP Antibodies as Measured by Histo-Blood Group Antigen HBGA Blocking Assay	Days 29	21.3 titer
NOR-204: GI.1/GII.4 (15/50/500) µg - MPL 15 µg, 1-Dose	Geometric Mean Blocking Titers 50 Percent (%) (GMBT50) of Anti-norovirus GI.1 VLP Antibodies as Measured by Histo-Blood Group Antigen HBGA Blocking Assay	Year 4	28.6 titer
NOR-204: GI.1/GII.4 (15/50/500) µg - MPL 15 µg, 1-Dose	Geometric Mean Blocking Titers 50 Percent (%) (GMBT50) of Anti-norovirus GI.1 VLP Antibodies as Measured by Histo-Blood Group Antigen HBGA Blocking Assay	Day 57	228.9 titer
NOR-204: GI.1/GII.4 (15/50/500) µg - MPL 15 µg, 1-Dose	Geometric Mean Blocking Titers 50 Percent (%) (GMBT50) of Anti-norovirus GI.1 VLP Antibodies as Measured by Histo-Blood Group Antigen HBGA Blocking Assay	Day 36	263.3 titer
NOR-204: GI.1/GII.4 (15/50/500) µg - MPL 15 µg, 1-Dose	Geometric Mean Blocking Titers 50 Percent (%) (GMBT50) of Anti-norovirus GI.1 VLP Antibodies as Measured by Histo-Blood Group Antigen HBGA Blocking Assay	Year 5	34.7 titer
NOR-204: GI.1/GII.4 (15/50/500) µg - MPL 15 µg, 1-Dose	Geometric Mean Blocking Titers 50 Percent (%) (GMBT50) of Anti-norovirus GI.1 VLP Antibodies as Measured by Histo-Blood Group Antigen HBGA Blocking Assay	Baseline	20.8 titer
NOR-204: GI.1/GII.4 (15/50/500) µg, 1-Dose (Age: 60-94 Yrs)	Geometric Mean Blocking Titers 50 Percent (%) (GMBT50) of Anti-norovirus GI.1 VLP Antibodies as Measured by Histo-Blood Group Antigen HBGA Blocking Assay	Day 211	96.5 titer
NOR-204: GI.1/GII.4 (15/50/500) µg, 1-Dose (Age: 60-94 Yrs)	Geometric Mean Blocking Titers 50 Percent (%) (GMBT50) of Anti-norovirus GI.1 VLP Antibodies as Measured by Histo-Blood Group Antigen HBGA Blocking Assay	Day 57	223.0 titer
NOR-204: GI.1/GII.4 (15/50/500) µg, 1-Dose (Age: 60-94 Yrs)	Geometric Mean Blocking Titers 50 Percent (%) (GMBT50) of Anti-norovirus GI.1 VLP Antibodies as Measured by Histo-Blood Group Antigen HBGA Blocking Assay	Day 36	213.4 titer
NOR-204: GI.1/GII.4 (15/50/500) µg, 1-Dose (Age: 60-94 Yrs)	Geometric Mean Blocking Titers 50 Percent (%) (GMBT50) of Anti-norovirus GI.1 VLP Antibodies as Measured by Histo-Blood Group Antigen HBGA Blocking Assay	Year 2	63.6 titer
NOR-204: GI.1/GII.4 (15/50/500) µg, 1-Dose (Age: 60-94 Yrs)	Geometric Mean Blocking Titers 50 Percent (%) (GMBT50) of Anti-norovirus GI.1 VLP Antibodies as Measured by Histo-Blood Group Antigen HBGA Blocking Assay	Days 29	28.7 titer
NOR-204: GI.1/GII.4 (15/50/500) µg, 1-Dose (Age: 60-94 Yrs)	Geometric Mean Blocking Titers 50 Percent (%) (GMBT50) of Anti-norovirus GI.1 VLP Antibodies as Measured by Histo-Blood Group Antigen HBGA Blocking Assay	Year 3	60.7 titer
NOR-204: GI.1/GII.4 (15/50/500) µg, 1-Dose (Age: 60-94 Yrs)	Geometric Mean Blocking Titers 50 Percent (%) (GMBT50) of Anti-norovirus GI.1 VLP Antibodies as Measured by Histo-Blood Group Antigen HBGA Blocking Assay	Baseline	28.9 titer
NOR-204: GI.1/GII.4 (15/50/500) µg, 1-Dose (Age: 60-94 Yrs)	Geometric Mean Blocking Titers 50 Percent (%) (GMBT50) of Anti-norovirus GI.1 VLP Antibodies as Measured by Histo-Blood Group Antigen HBGA Blocking Assay	Year 4	45.9 titer
NOR-204: GI.1/GII.4 (15/50/500) µg, 1-Dose (Age: 60-94 Yrs)	Geometric Mean Blocking Titers 50 Percent (%) (GMBT50) of Anti-norovirus GI.1 VLP Antibodies as Measured by Histo-Blood Group Antigen HBGA Blocking Assay	Year 5	41.9 titer
NOR-204: GI.1/GII.4 (15/50/500) µg, 1-Dose (Age: 18-49 Yrs)	Geometric Mean Blocking Titers 50 Percent (%) (GMBT50) of Anti-norovirus GI.1 VLP Antibodies as Measured by Histo-Blood Group Antigen HBGA Blocking Assay	Year 5	31.9 titer
NOR-204: GI.1/GII.4 (15/50/500) µg, 1-Dose (Age: 18-49 Yrs)	Geometric Mean Blocking Titers 50 Percent (%) (GMBT50) of Anti-norovirus GI.1 VLP Antibodies as Measured by Histo-Blood Group Antigen HBGA Blocking Assay	Year 3	34.0 titer
NOR-204: GI.1/GII.4 (15/50/500) µg, 1-Dose (Age: 18-49 Yrs)	Geometric Mean Blocking Titers 50 Percent (%) (GMBT50) of Anti-norovirus GI.1 VLP Antibodies as Measured by Histo-Blood Group Antigen HBGA Blocking Assay	Year 2	38.9 titer
NOR-204: GI.1/GII.4 (15/50/500) µg, 1-Dose (Age: 18-49 Yrs)	Geometric Mean Blocking Titers 50 Percent (%) (GMBT50) of Anti-norovirus GI.1 VLP Antibodies as Measured by Histo-Blood Group Antigen HBGA Blocking Assay	Days 29	19.9 titer
NOR-204: GI.1/GII.4 (15/50/500) µg, 1-Dose (Age: 18-49 Yrs)	Geometric Mean Blocking Titers 50 Percent (%) (GMBT50) of Anti-norovirus GI.1 VLP Antibodies as Measured by Histo-Blood Group Antigen HBGA Blocking Assay	Day 57	105.1 titer
NOR-204: GI.1/GII.4 (15/50/500) µg, 1-Dose (Age: 18-49 Yrs)	Geometric Mean Blocking Titers 50 Percent (%) (GMBT50) of Anti-norovirus GI.1 VLP Antibodies as Measured by Histo-Blood Group Antigen HBGA Blocking Assay	Day 211	43.4 titer
NOR-204: GI.1/GII.4 (15/50/500) µg, 1-Dose (Age: 18-49 Yrs)	Geometric Mean Blocking Titers 50 Percent (%) (GMBT50) of Anti-norovirus GI.1 VLP Antibodies as Measured by Histo-Blood Group Antigen HBGA Blocking Assay	Year 4	28.3 titer
NOR-204: GI.1/GII.4 (15/50/500) µg, 1-Dose (Age: 18-49 Yrs)	Geometric Mean Blocking Titers 50 Percent (%) (GMBT50) of Anti-norovirus GI.1 VLP Antibodies as Measured by Histo-Blood Group Antigen HBGA Blocking Assay	Baseline	18.7 titer
NOR-204: GI.1/GII.4 (15/50/500) µg, 1-Dose (Age: 18-49 Yrs)	Geometric Mean Blocking Titers 50 Percent (%) (GMBT50) of Anti-norovirus GI.1 VLP Antibodies as Measured by Histo-Blood Group Antigen HBGA Blocking Assay	Day 36	155.3 titer
NOR-204: GI.1/GII.4 (15/50/500) µg - MPL 15 µg, 2-Dose	Geometric Mean Blocking Titers 50 Percent (%) (GMBT50) of Anti-norovirus GI.1 VLP Antibodies as Measured by Histo-Blood Group Antigen HBGA Blocking Assay	Day 211	132.9 titer
NOR-204: GI.1/GII.4 (15/50/500) µg - MPL 15 µg, 2-Dose	Geometric Mean Blocking Titers 50 Percent (%) (GMBT50) of Anti-norovirus GI.1 VLP Antibodies as Measured by Histo-Blood Group Antigen HBGA Blocking Assay	Year 3	72.5 titer
NOR-204: GI.1/GII.4 (15/50/500) µg - MPL 15 µg, 2-Dose	Geometric Mean Blocking Titers 50 Percent (%) (GMBT50) of Anti-norovirus GI.1 VLP Antibodies as Measured by Histo-Blood Group Antigen HBGA Blocking Assay	Day 57	362.5 titer
NOR-204: GI.1/GII.4 (15/50/500) µg - MPL 15 µg, 2-Dose	Geometric Mean Blocking Titers 50 Percent (%) (GMBT50) of Anti-norovirus GI.1 VLP Antibodies as Measured by Histo-Blood Group Antigen HBGA Blocking Assay	Year 4	76.1 titer
NOR-204: GI.1/GII.4 (15/50/500) µg - MPL 15 µg, 2-Dose	Geometric Mean Blocking Titers 50 Percent (%) (GMBT50) of Anti-norovirus GI.1 VLP Antibodies as Measured by Histo-Blood Group Antigen HBGA Blocking Assay	Year 2	58.9 titer
NOR-204: GI.1/GII.4 (15/50/500) µg - MPL 15 µg, 2-Dose	Geometric Mean Blocking Titers 50 Percent (%) (GMBT50) of Anti-norovirus GI.1 VLP Antibodies as Measured by Histo-Blood Group Antigen HBGA Blocking Assay	Baseline	23.9 titer
NOR-204: GI.1/GII.4 (15/50/500) µg - MPL 15 µg, 2-Dose	Geometric Mean Blocking Titers 50 Percent (%) (GMBT50) of Anti-norovirus GI.1 VLP Antibodies as Measured by Histo-Blood Group Antigen HBGA Blocking Assay	Days 29	342.5 titer
NOR-204: GI.1/GII.4 (15/50/500) µg - MPL 15 µg, 2-Dose	Geometric Mean Blocking Titers 50 Percent (%) (GMBT50) of Anti-norovirus GI.1 VLP Antibodies as Measured by Histo-Blood Group Antigen HBGA Blocking Assay	Day 36	406.4 titer
NOR-204: GI.1/GII.4 (15/50/500) µg - MPL 15 µg, 2-Dose	Geometric Mean Blocking Titers 50 Percent (%) (GMBT50) of Anti-norovirus GI.1 VLP Antibodies as Measured by Histo-Blood Group Antigen HBGA Blocking Assay	Year 5	59.8 titer
NOR-204: GI.1/GII.4 (15/50/500) µg, 2-Dose	Geometric Mean Blocking Titers 50 Percent (%) (GMBT50) of Anti-norovirus GI.1 VLP Antibodies as Measured by Histo-Blood Group Antigen HBGA Blocking Assay	Year 2	83.4 titer
NOR-204: GI.1/GII.4 (15/50/500) µg, 2-Dose	Geometric Mean Blocking Titers 50 Percent (%) (GMBT50) of Anti-norovirus GI.1 VLP Antibodies as Measured by Histo-Blood Group Antigen HBGA Blocking Assay	Days 29	329.2 titer
NOR-204: GI.1/GII.4 (15/50/500) µg, 2-Dose	Geometric Mean Blocking Titers 50 Percent (%) (GMBT50) of Anti-norovirus GI.1 VLP Antibodies as Measured by Histo-Blood Group Antigen HBGA Blocking Assay	Year 4	57.1 titer
NOR-204: GI.1/GII.4 (15/50/500) µg, 2-Dose	Geometric Mean Blocking Titers 50 Percent (%) (GMBT50) of Anti-norovirus GI.1 VLP Antibodies as Measured by Histo-Blood Group Antigen HBGA Blocking Assay	Baseline	26.4 titer
NOR-204: GI.1/GII.4 (15/50/500) µg, 2-Dose	Geometric Mean Blocking Titers 50 Percent (%) (GMBT50) of Anti-norovirus GI.1 VLP Antibodies as Measured by Histo-Blood Group Antigen HBGA Blocking Assay	Day 36	307.2 titer
NOR-204: GI.1/GII.4 (15/50/500) µg, 2-Dose	Geometric Mean Blocking Titers 50 Percent (%) (GMBT50) of Anti-norovirus GI.1 VLP Antibodies as Measured by Histo-Blood Group Antigen HBGA Blocking Assay	Year 3	76.1 titer
NOR-204: GI.1/GII.4 (15/50/500) µg, 2-Dose	Geometric Mean Blocking Titers 50 Percent (%) (GMBT50) of Anti-norovirus GI.1 VLP Antibodies as Measured by Histo-Blood Group Antigen HBGA Blocking Assay	Day 57	304.3 titer
NOR-204: GI.1/GII.4 (15/50/500) µg, 2-Dose	Geometric Mean Blocking Titers 50 Percent (%) (GMBT50) of Anti-norovirus GI.1 VLP Antibodies as Measured by Histo-Blood Group Antigen HBGA Blocking Assay	Day 211	126.6 titer
NOR-204: GI.1/GII.4 (15/50/500) µg, 2-Dose	Geometric Mean Blocking Titers 50 Percent (%) (GMBT50) of Anti-norovirus GI.1 VLP Antibodies as Measured by Histo-Blood Group Antigen HBGA Blocking Assay	Year 5	65.5 titer

Secondary

Geometric Mean Titers (GMT) of Anti-norovirus GI.1 VLP Antibodies as Measured by Total Immunoglobulin (Pan-Ig) Enzyme-linked Immunosorbent Assay (ELISA)

GMT of anti-norovirus GI.1 VLP antibody titers as measured by total immunoglobulin (pan-Ig) enzyme-linked immunoassay (ELISA). Data reported for up to Year 5 was collected at Baseline (NOR-107, NOR-210, NOR-204), at Days 28 (NOR-107), 29 (NOR-204 and NOR-210), Day 36 (NOR-204), Day 56 (NOR-107) and Day 57 (NOR-204), Day 208 (NOR-107) and Day 211 (NOR-204), Year 2 (NOR-204 and NOR-210) Years 3, 4 and 5(NOR-107,NOR-210, NOR-204).

Time frame: Baseline up to Year 2 post-primary vaccination of initial study NOR-107, NOR-210 NOR-204 and up to Year 5 of this extension study

Arm	Measure	Group	Value (GEOMETRIC_MEAN)
NOR-107: GI.1/GII.4 (15/15/500) μg- MPL 50 μg,1-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GI.1 VLP Antibodies as Measured by Total Immunoglobulin (Pan-Ig) Enzyme-linked Immunosorbent Assay (ELISA)	Day 56	15032.5 titer
NOR-107: GI.1/GII.4 (15/15/500) μg- MPL 50 μg,1-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GI.1 VLP Antibodies as Measured by Total Immunoglobulin (Pan-Ig) Enzyme-linked Immunosorbent Assay (ELISA)	Baseline	1030.5 titer
NOR-107: GI.1/GII.4 (15/15/500) μg- MPL 50 μg,1-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GI.1 VLP Antibodies as Measured by Total Immunoglobulin (Pan-Ig) Enzyme-linked Immunosorbent Assay (ELISA)	Year 4	2095.5 titer
NOR-107: GI.1/GII.4 (15/15/500) μg- MPL 50 μg,1-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GI.1 VLP Antibodies as Measured by Total Immunoglobulin (Pan-Ig) Enzyme-linked Immunosorbent Assay (ELISA)	Day 208	6015.9 titer
NOR-107: GI.1/GII.4 (15/15/500) μg- MPL 50 μg,1-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GI.1 VLP Antibodies as Measured by Total Immunoglobulin (Pan-Ig) Enzyme-linked Immunosorbent Assay (ELISA)	Year 5	1732.3 titer
NOR-107: GI.1/GII.4 (15/15/500) μg- MPL 50 μg,1-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GI.1 VLP Antibodies as Measured by Total Immunoglobulin (Pan-Ig) Enzyme-linked Immunosorbent Assay (ELISA)	Year 3	2229.0 titer
NOR-107: GI.1/GII.4 (15/15/500) μg- MPL 50 μg,1-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GI.1 VLP Antibodies as Measured by Total Immunoglobulin (Pan-Ig) Enzyme-linked Immunosorbent Assay (ELISA)	Day 28	975.2 titer
NOR-107: GI.1/GII.4 (15/50/500) μg- MPL 50 μg,1-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GI.1 VLP Antibodies as Measured by Total Immunoglobulin (Pan-Ig) Enzyme-linked Immunosorbent Assay (ELISA)	Year 3	1493.3 titer
NOR-107: GI.1/GII.4 (15/50/500) μg- MPL 50 μg,1-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GI.1 VLP Antibodies as Measured by Total Immunoglobulin (Pan-Ig) Enzyme-linked Immunosorbent Assay (ELISA)	Day 28	649.3 titer
NOR-107: GI.1/GII.4 (15/50/500) μg- MPL 50 μg,1-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GI.1 VLP Antibodies as Measured by Total Immunoglobulin (Pan-Ig) Enzyme-linked Immunosorbent Assay (ELISA)	Baseline	689.8 titer
NOR-107: GI.1/GII.4 (15/50/500) μg- MPL 50 μg,1-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GI.1 VLP Antibodies as Measured by Total Immunoglobulin (Pan-Ig) Enzyme-linked Immunosorbent Assay (ELISA)	Day 56	12246.2 titer
NOR-107: GI.1/GII.4 (15/50/500) μg- MPL 50 μg,1-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GI.1 VLP Antibodies as Measured by Total Immunoglobulin (Pan-Ig) Enzyme-linked Immunosorbent Assay (ELISA)	Year 5	1563.6 titer
NOR-107: GI.1/GII.4 (15/50/500) μg- MPL 50 μg,1-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GI.1 VLP Antibodies as Measured by Total Immunoglobulin (Pan-Ig) Enzyme-linked Immunosorbent Assay (ELISA)	Day 208	4784.5 titer
NOR-107: GI.1/GII.4 (15/50/500) μg- MPL 50 μg,1-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GI.1 VLP Antibodies as Measured by Total Immunoglobulin (Pan-Ig) Enzyme-linked Immunosorbent Assay (ELISA)	Year 4	1727.7 titer
NOR-107: GI.1/GII.4 (50/50/500) μg- MPL 50 μg,1-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GI.1 VLP Antibodies as Measured by Total Immunoglobulin (Pan-Ig) Enzyme-linked Immunosorbent Assay (ELISA)	Baseline	646.2 titer
NOR-107: GI.1/GII.4 (50/50/500) μg- MPL 50 μg,1-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GI.1 VLP Antibodies as Measured by Total Immunoglobulin (Pan-Ig) Enzyme-linked Immunosorbent Assay (ELISA)	Year 4	2541.1 titer
NOR-107: GI.1/GII.4 (50/50/500) μg- MPL 50 μg,1-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GI.1 VLP Antibodies as Measured by Total Immunoglobulin (Pan-Ig) Enzyme-linked Immunosorbent Assay (ELISA)	Day 208	6231.0 titer
NOR-107: GI.1/GII.4 (50/50/500) μg- MPL 50 μg,1-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GI.1 VLP Antibodies as Measured by Total Immunoglobulin (Pan-Ig) Enzyme-linked Immunosorbent Assay (ELISA)	Year 3	2058.7 titer
NOR-107: GI.1/GII.4 (50/50/500) μg- MPL 50 μg,1-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GI.1 VLP Antibodies as Measured by Total Immunoglobulin (Pan-Ig) Enzyme-linked Immunosorbent Assay (ELISA)	Year 5	2345.8 titer
NOR-107: GI.1/GII.4 (50/50/500) μg- MPL 50 μg,1-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GI.1 VLP Antibodies as Measured by Total Immunoglobulin (Pan-Ig) Enzyme-linked Immunosorbent Assay (ELISA)	Day 28	544.9 titer
NOR-107: GI.1/GII.4 (50/50/500) μg- MPL 50 μg,1-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GI.1 VLP Antibodies as Measured by Total Immunoglobulin (Pan-Ig) Enzyme-linked Immunosorbent Assay (ELISA)	Day 56	16739.1 titer
NOR-107: GI.1/GII.4 (15/15/500) μg- MPL 15 μg,1-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GI.1 VLP Antibodies as Measured by Total Immunoglobulin (Pan-Ig) Enzyme-linked Immunosorbent Assay (ELISA)	Baseline	620.9 titer
NOR-107: GI.1/GII.4 (15/15/500) μg- MPL 15 μg,1-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GI.1 VLP Antibodies as Measured by Total Immunoglobulin (Pan-Ig) Enzyme-linked Immunosorbent Assay (ELISA)	Year 5	2009.8 titer
NOR-107: GI.1/GII.4 (15/15/500) μg- MPL 15 μg,1-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GI.1 VLP Antibodies as Measured by Total Immunoglobulin (Pan-Ig) Enzyme-linked Immunosorbent Assay (ELISA)	Day 28	648.7 titer
NOR-107: GI.1/GII.4 (15/15/500) μg- MPL 15 μg,1-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GI.1 VLP Antibodies as Measured by Total Immunoglobulin (Pan-Ig) Enzyme-linked Immunosorbent Assay (ELISA)	Year 3	2227.0 titer
NOR-107: GI.1/GII.4 (15/15/500) μg- MPL 15 μg,1-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GI.1 VLP Antibodies as Measured by Total Immunoglobulin (Pan-Ig) Enzyme-linked Immunosorbent Assay (ELISA)	Year 4	1958.2 titer
NOR-107: GI.1/GII.4 (15/15/500) μg- MPL 15 μg,1-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GI.1 VLP Antibodies as Measured by Total Immunoglobulin (Pan-Ig) Enzyme-linked Immunosorbent Assay (ELISA)	Day 208	5675.5 titer
NOR-107: GI.1/GII.4 (15/15/500) μg- MPL 15 μg,1-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GI.1 VLP Antibodies as Measured by Total Immunoglobulin (Pan-Ig) Enzyme-linked Immunosorbent Assay (ELISA)	Day 56	13673.2 titer
NOR-107: GI.1/GII.4 (15/50/500) μg- MPL 15 μg,1-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GI.1 VLP Antibodies as Measured by Total Immunoglobulin (Pan-Ig) Enzyme-linked Immunosorbent Assay (ELISA)	Day 208	4212.3 titer
NOR-107: GI.1/GII.4 (15/50/500) μg- MPL 15 μg,1-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GI.1 VLP Antibodies as Measured by Total Immunoglobulin (Pan-Ig) Enzyme-linked Immunosorbent Assay (ELISA)	Day 28	475.4 titer
NOR-107: GI.1/GII.4 (15/50/500) μg- MPL 15 μg,1-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GI.1 VLP Antibodies as Measured by Total Immunoglobulin (Pan-Ig) Enzyme-linked Immunosorbent Assay (ELISA)	Baseline	547.4 titer
NOR-107: GI.1/GII.4 (15/50/500) μg- MPL 15 μg,1-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GI.1 VLP Antibodies as Measured by Total Immunoglobulin (Pan-Ig) Enzyme-linked Immunosorbent Assay (ELISA)	Day 56	12847.2 titer
NOR-107: GI.1/GII.4 (15/50/500) μg- MPL 15 μg,1-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GI.1 VLP Antibodies as Measured by Total Immunoglobulin (Pan-Ig) Enzyme-linked Immunosorbent Assay (ELISA)	Year 5	1664.8 titer
NOR-107: GI.1/GII.4 (15/50/500) μg- MPL 15 μg,1-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GI.1 VLP Antibodies as Measured by Total Immunoglobulin (Pan-Ig) Enzyme-linked Immunosorbent Assay (ELISA)	Year 3	1465.7 titer
NOR-107: GI.1/GII.4 (15/50/500) μg- MPL 15 μg,1-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GI.1 VLP Antibodies as Measured by Total Immunoglobulin (Pan-Ig) Enzyme-linked Immunosorbent Assay (ELISA)	Year 4	1802.9 titer
NOR-107: GI.1/GII.4 (50/50/500) μg- MPL 15 μg,1-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GI.1 VLP Antibodies as Measured by Total Immunoglobulin (Pan-Ig) Enzyme-linked Immunosorbent Assay (ELISA)	Baseline	539.6 titer
NOR-107: GI.1/GII.4 (50/50/500) μg- MPL 15 μg,1-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GI.1 VLP Antibodies as Measured by Total Immunoglobulin (Pan-Ig) Enzyme-linked Immunosorbent Assay (ELISA)	Day 56	18464.0 titer
NOR-107: GI.1/GII.4 (50/50/500) μg- MPL 15 μg,1-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GI.1 VLP Antibodies as Measured by Total Immunoglobulin (Pan-Ig) Enzyme-linked Immunosorbent Assay (ELISA)	Day 28	535.4 titer
NOR-107: GI.1/GII.4 (50/50/500) μg- MPL 15 μg,1-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GI.1 VLP Antibodies as Measured by Total Immunoglobulin (Pan-Ig) Enzyme-linked Immunosorbent Assay (ELISA)	Year 5	1781.2 titer
NOR-107: GI.1/GII.4 (50/50/500) μg- MPL 15 μg,1-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GI.1 VLP Antibodies as Measured by Total Immunoglobulin (Pan-Ig) Enzyme-linked Immunosorbent Assay (ELISA)	Year 4	1565.5 titer
NOR-107: GI.1/GII.4 (50/50/500) μg- MPL 15 μg,1-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GI.1 VLP Antibodies as Measured by Total Immunoglobulin (Pan-Ig) Enzyme-linked Immunosorbent Assay (ELISA)	Day 208	4997.4 titer
NOR-107: GI.1/GII.4 (50/50/500) μg- MPL 15 μg,1-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GI.1 VLP Antibodies as Measured by Total Immunoglobulin (Pan-Ig) Enzyme-linked Immunosorbent Assay (ELISA)	Year 3	1568.0 titer
NOR-107: GI.1/GII.4 (15/15/500) μg,1-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GI.1 VLP Antibodies as Measured by Total Immunoglobulin (Pan-Ig) Enzyme-linked Immunosorbent Assay (ELISA)	Day 208	5577.8 titer
NOR-107: GI.1/GII.4 (15/15/500) μg,1-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GI.1 VLP Antibodies as Measured by Total Immunoglobulin (Pan-Ig) Enzyme-linked Immunosorbent Assay (ELISA)	Day 56	15242.3 titer
NOR-107: GI.1/GII.4 (15/15/500) μg,1-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GI.1 VLP Antibodies as Measured by Total Immunoglobulin (Pan-Ig) Enzyme-linked Immunosorbent Assay (ELISA)	Year 3	2156.1 titer
NOR-107: GI.1/GII.4 (15/15/500) μg,1-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GI.1 VLP Antibodies as Measured by Total Immunoglobulin (Pan-Ig) Enzyme-linked Immunosorbent Assay (ELISA)	Year 4	2934.1 titer
NOR-107: GI.1/GII.4 (15/15/500) μg,1-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GI.1 VLP Antibodies as Measured by Total Immunoglobulin (Pan-Ig) Enzyme-linked Immunosorbent Assay (ELISA)	Year 5	2116.5 titer
NOR-107: GI.1/GII.4 (15/15/500) μg,1-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GI.1 VLP Antibodies as Measured by Total Immunoglobulin (Pan-Ig) Enzyme-linked Immunosorbent Assay (ELISA)	Baseline	1089.2 titer
NOR-107: GI.1/GII.4 (15/15/500) μg,1-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GI.1 VLP Antibodies as Measured by Total Immunoglobulin (Pan-Ig) Enzyme-linked Immunosorbent Assay (ELISA)	Day 28	1086.1 titer
NOR-107: GI.1/GII.4 (15/50/500) μg,1-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GI.1 VLP Antibodies as Measured by Total Immunoglobulin (Pan-Ig) Enzyme-linked Immunosorbent Assay (ELISA)	Year 5	2270.3 titer
NOR-107: GI.1/GII.4 (15/50/500) μg,1-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GI.1 VLP Antibodies as Measured by Total Immunoglobulin (Pan-Ig) Enzyme-linked Immunosorbent Assay (ELISA)	Baseline	856.1 titer
NOR-107: GI.1/GII.4 (15/50/500) μg,1-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GI.1 VLP Antibodies as Measured by Total Immunoglobulin (Pan-Ig) Enzyme-linked Immunosorbent Assay (ELISA)	Year 4	2107.0 titer
NOR-107: GI.1/GII.4 (15/50/500) μg,1-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GI.1 VLP Antibodies as Measured by Total Immunoglobulin (Pan-Ig) Enzyme-linked Immunosorbent Assay (ELISA)	Day 28	839.1 titer
NOR-107: GI.1/GII.4 (15/50/500) μg,1-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GI.1 VLP Antibodies as Measured by Total Immunoglobulin (Pan-Ig) Enzyme-linked Immunosorbent Assay (ELISA)	Year 3	1913.2 titer
NOR-107: GI.1/GII.4 (15/50/500) μg,1-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GI.1 VLP Antibodies as Measured by Total Immunoglobulin (Pan-Ig) Enzyme-linked Immunosorbent Assay (ELISA)	Day 56	15071.0 titer
NOR-107: GI.1/GII.4 (15/50/500) μg,1-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GI.1 VLP Antibodies as Measured by Total Immunoglobulin (Pan-Ig) Enzyme-linked Immunosorbent Assay (ELISA)	Day 208	6686.7 titer
NOR-107: GI.1/GII.4 (50/50/500) μg,1-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GI.1 VLP Antibodies as Measured by Total Immunoglobulin (Pan-Ig) Enzyme-linked Immunosorbent Assay (ELISA)	Year 4	1965.0 titer
NOR-107: GI.1/GII.4 (50/50/500) μg,1-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GI.1 VLP Antibodies as Measured by Total Immunoglobulin (Pan-Ig) Enzyme-linked Immunosorbent Assay (ELISA)	Year 5	2181.9 titer
NOR-107: GI.1/GII.4 (50/50/500) μg,1-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GI.1 VLP Antibodies as Measured by Total Immunoglobulin (Pan-Ig) Enzyme-linked Immunosorbent Assay (ELISA)	Day 208	7761.2 titer
NOR-107: GI.1/GII.4 (50/50/500) μg,1-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GI.1 VLP Antibodies as Measured by Total Immunoglobulin (Pan-Ig) Enzyme-linked Immunosorbent Assay (ELISA)	Day 28	729.3 titer
NOR-107: GI.1/GII.4 (50/50/500) μg,1-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GI.1 VLP Antibodies as Measured by Total Immunoglobulin (Pan-Ig) Enzyme-linked Immunosorbent Assay (ELISA)	Day 56	25738.6 titer
NOR-107: GI.1/GII.4 (50/50/500) μg,1-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GI.1 VLP Antibodies as Measured by Total Immunoglobulin (Pan-Ig) Enzyme-linked Immunosorbent Assay (ELISA)	Year 3	2063.1 titer
NOR-107: GI.1/GII.4 (50/50/500) μg,1-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GI.1 VLP Antibodies as Measured by Total Immunoglobulin (Pan-Ig) Enzyme-linked Immunosorbent Assay (ELISA)	Baseline	749.7 titer
NOR-107: GI.1/GII.4 (50/150/500) μg,1-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GI.1 VLP Antibodies as Measured by Total Immunoglobulin (Pan-Ig) Enzyme-linked Immunosorbent Assay (ELISA)	Day 56	14709.3 titer
NOR-107: GI.1/GII.4 (50/150/500) μg,1-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GI.1 VLP Antibodies as Measured by Total Immunoglobulin (Pan-Ig) Enzyme-linked Immunosorbent Assay (ELISA)	Baseline	770.6 titer
NOR-107: GI.1/GII.4 (50/150/500) μg,1-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GI.1 VLP Antibodies as Measured by Total Immunoglobulin (Pan-Ig) Enzyme-linked Immunosorbent Assay (ELISA)	Year 5	1811.9 titer
NOR-107: GI.1/GII.4 (50/150/500) μg,1-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GI.1 VLP Antibodies as Measured by Total Immunoglobulin (Pan-Ig) Enzyme-linked Immunosorbent Assay (ELISA)	Day 208	5274.3 titer
NOR-107: GI.1/GII.4 (50/150/500) μg,1-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GI.1 VLP Antibodies as Measured by Total Immunoglobulin (Pan-Ig) Enzyme-linked Immunosorbent Assay (ELISA)	Year 4	1679.0 titer
NOR-107: GI.1/GII.4 (50/150/500) μg,1-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GI.1 VLP Antibodies as Measured by Total Immunoglobulin (Pan-Ig) Enzyme-linked Immunosorbent Assay (ELISA)	Year 3	1702.4 titer
NOR-107: GI.1/GII.4 (50/150/500) μg,1-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GI.1 VLP Antibodies as Measured by Total Immunoglobulin (Pan-Ig) Enzyme-linked Immunosorbent Assay (ELISA)	Day 28	731.0 titer
NOR-107: GI.1/GII.4 (15/50/167) μg,1-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GI.1 VLP Antibodies as Measured by Total Immunoglobulin (Pan-Ig) Enzyme-linked Immunosorbent Assay (ELISA)	Year 5	1434.9 titer
NOR-107: GI.1/GII.4 (15/50/167) μg,1-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GI.1 VLP Antibodies as Measured by Total Immunoglobulin (Pan-Ig) Enzyme-linked Immunosorbent Assay (ELISA)	Day 208	4978.7 titer
NOR-107: GI.1/GII.4 (15/50/167) μg,1-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GI.1 VLP Antibodies as Measured by Total Immunoglobulin (Pan-Ig) Enzyme-linked Immunosorbent Assay (ELISA)	Year 3	1579.5 titer
NOR-107: GI.1/GII.4 (15/50/167) μg,1-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GI.1 VLP Antibodies as Measured by Total Immunoglobulin (Pan-Ig) Enzyme-linked Immunosorbent Assay (ELISA)	Baseline	925.3 titer
NOR-107: GI.1/GII.4 (15/50/167) μg,1-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GI.1 VLP Antibodies as Measured by Total Immunoglobulin (Pan-Ig) Enzyme-linked Immunosorbent Assay (ELISA)	Day 28	932.8 titer
NOR-107: GI.1/GII.4 (15/50/167) μg,1-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GI.1 VLP Antibodies as Measured by Total Immunoglobulin (Pan-Ig) Enzyme-linked Immunosorbent Assay (ELISA)	Year 4	2025.2 titer
NOR-107: GI.1/GII.4 (15/50/167) μg,1-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GI.1 VLP Antibodies as Measured by Total Immunoglobulin (Pan-Ig) Enzyme-linked Immunosorbent Assay (ELISA)	Day 56	12428.4 titer
NOR-107: GI.1/GII.4 (15/50/500) μg,2-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GI.1 VLP Antibodies as Measured by Total Immunoglobulin (Pan-Ig) Enzyme-linked Immunosorbent Assay (ELISA)	Baseline	777.3 titer
NOR-107: GI.1/GII.4 (15/50/500) μg,2-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GI.1 VLP Antibodies as Measured by Total Immunoglobulin (Pan-Ig) Enzyme-linked Immunosorbent Assay (ELISA)	Year 5	2036.9 titer
NOR-107: GI.1/GII.4 (15/50/500) μg,2-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GI.1 VLP Antibodies as Measured by Total Immunoglobulin (Pan-Ig) Enzyme-linked Immunosorbent Assay (ELISA)	Year 4	2335.8 titer
NOR-107: GI.1/GII.4 (15/50/500) μg,2-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GI.1 VLP Antibodies as Measured by Total Immunoglobulin (Pan-Ig) Enzyme-linked Immunosorbent Assay (ELISA)	Day 56	14302.9 titer
NOR-107: GI.1/GII.4 (15/50/500) μg,2-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GI.1 VLP Antibodies as Measured by Total Immunoglobulin (Pan-Ig) Enzyme-linked Immunosorbent Assay (ELISA)	Year 3	2422.7 titer
NOR-107: GI.1/GII.4 (15/50/500) μg,2-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GI.1 VLP Antibodies as Measured by Total Immunoglobulin (Pan-Ig) Enzyme-linked Immunosorbent Assay (ELISA)	Day 208	7082.7 titer
NOR-107: GI.1/GII.4 (15/50/500) μg,2-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GI.1 VLP Antibodies as Measured by Total Immunoglobulin (Pan-Ig) Enzyme-linked Immunosorbent Assay (ELISA)	Day 28	16822.8 titer
NOR-107: GI.1/GII.4 (50/150/500) μg,2-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GI.1 VLP Antibodies as Measured by Total Immunoglobulin (Pan-Ig) Enzyme-linked Immunosorbent Assay (ELISA)	Day 28	21215.2 titer
NOR-107: GI.1/GII.4 (50/150/500) μg,2-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GI.1 VLP Antibodies as Measured by Total Immunoglobulin (Pan-Ig) Enzyme-linked Immunosorbent Assay (ELISA)	Year 3	2914.8 titer
NOR-107: GI.1/GII.4 (50/150/500) μg,2-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GI.1 VLP Antibodies as Measured by Total Immunoglobulin (Pan-Ig) Enzyme-linked Immunosorbent Assay (ELISA)	Year 4	2635.7 titer
NOR-107: GI.1/GII.4 (50/150/500) μg,2-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GI.1 VLP Antibodies as Measured by Total Immunoglobulin (Pan-Ig) Enzyme-linked Immunosorbent Assay (ELISA)	Day 208	7469.9 titer
NOR-107: GI.1/GII.4 (50/150/500) μg,2-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GI.1 VLP Antibodies as Measured by Total Immunoglobulin (Pan-Ig) Enzyme-linked Immunosorbent Assay (ELISA)	Year 5	2405.4 titer
NOR-107: GI.1/GII.4 (50/150/500) μg,2-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GI.1 VLP Antibodies as Measured by Total Immunoglobulin (Pan-Ig) Enzyme-linked Immunosorbent Assay (ELISA)	Day 56	18086.8 titer
NOR-107: GI.1/GII.4 (50/150/500) μg,2-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GI.1 VLP Antibodies as Measured by Total Immunoglobulin (Pan-Ig) Enzyme-linked Immunosorbent Assay (ELISA)	Baseline	908.6 titer
NOR-107: GI.1/GII.4 (15/50/167) μg,2-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GI.1 VLP Antibodies as Measured by Total Immunoglobulin (Pan-Ig) Enzyme-linked Immunosorbent Assay (ELISA)	Year 4	2016.6 titer
NOR-107: GI.1/GII.4 (15/50/167) μg,2-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GI.1 VLP Antibodies as Measured by Total Immunoglobulin (Pan-Ig) Enzyme-linked Immunosorbent Assay (ELISA)	Day 28	14102.7 titer
NOR-107: GI.1/GII.4 (15/50/167) μg,2-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GI.1 VLP Antibodies as Measured by Total Immunoglobulin (Pan-Ig) Enzyme-linked Immunosorbent Assay (ELISA)	Day 208	5355.9 titer
NOR-107: GI.1/GII.4 (15/50/167) μg,2-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GI.1 VLP Antibodies as Measured by Total Immunoglobulin (Pan-Ig) Enzyme-linked Immunosorbent Assay (ELISA)	Year 3	2077.8 titer
NOR-107: GI.1/GII.4 (15/50/167) μg,2-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GI.1 VLP Antibodies as Measured by Total Immunoglobulin (Pan-Ig) Enzyme-linked Immunosorbent Assay (ELISA)	Year 5	1817.7 titer
NOR-107: GI.1/GII.4 (15/50/167) μg,2-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GI.1 VLP Antibodies as Measured by Total Immunoglobulin (Pan-Ig) Enzyme-linked Immunosorbent Assay (ELISA)	Baseline	640.4 titer
NOR-107: GI.1/GII.4 (15/50/167) μg,2-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GI.1 VLP Antibodies as Measured by Total Immunoglobulin (Pan-Ig) Enzyme-linked Immunosorbent Assay (ELISA)	Day 56	11282.4 titer
NOR-210: GI.1/GII.4 (15/50/500) µg, 1-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GI.1 VLP Antibodies as Measured by Total Immunoglobulin (Pan-Ig) Enzyme-linked Immunosorbent Assay (ELISA)	Year 2	1662.0 titer
NOR-210: GI.1/GII.4 (15/50/500) µg, 1-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GI.1 VLP Antibodies as Measured by Total Immunoglobulin (Pan-Ig) Enzyme-linked Immunosorbent Assay (ELISA)	Year 3	1500.9 titer
NOR-210: GI.1/GII.4 (15/50/500) µg, 1-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GI.1 VLP Antibodies as Measured by Total Immunoglobulin (Pan-Ig) Enzyme-linked Immunosorbent Assay (ELISA)	Year 5	1803.8 titer
NOR-210: GI.1/GII.4 (15/50/500) µg, 1-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GI.1 VLP Antibodies as Measured by Total Immunoglobulin (Pan-Ig) Enzyme-linked Immunosorbent Assay (ELISA)	Year 4	1627.4 titer
NOR-210: GI.1/GII.4 (15/50/500) µg, 1-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GI.1 VLP Antibodies as Measured by Total Immunoglobulin (Pan-Ig) Enzyme-linked Immunosorbent Assay (ELISA)	Baseline	160.1 titer
NOR-210: GI.1/GII.4 (15/50/500) µg, 1-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GI.1 VLP Antibodies as Measured by Total Immunoglobulin (Pan-Ig) Enzyme-linked Immunosorbent Assay (ELISA)	Day 29	10798.6 titer
NOR-204: GI.1/GII.4 (15/50/500) µg - MPL 15 µg, 1-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GI.1 VLP Antibodies as Measured by Total Immunoglobulin (Pan-Ig) Enzyme-linked Immunosorbent Assay (ELISA)	Baseline	671.5 titer
NOR-204: GI.1/GII.4 (15/50/500) µg - MPL 15 µg, 1-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GI.1 VLP Antibodies as Measured by Total Immunoglobulin (Pan-Ig) Enzyme-linked Immunosorbent Assay (ELISA)	Year 3	2006.4 titer
NOR-204: GI.1/GII.4 (15/50/500) µg - MPL 15 µg, 1-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GI.1 VLP Antibodies as Measured by Total Immunoglobulin (Pan-Ig) Enzyme-linked Immunosorbent Assay (ELISA)	Day 36	6915.9 titer
NOR-204: GI.1/GII.4 (15/50/500) µg - MPL 15 µg, 1-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GI.1 VLP Antibodies as Measured by Total Immunoglobulin (Pan-Ig) Enzyme-linked Immunosorbent Assay (ELISA)	Year 2	1804.4 titer
NOR-204: GI.1/GII.4 (15/50/500) µg - MPL 15 µg, 1-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GI.1 VLP Antibodies as Measured by Total Immunoglobulin (Pan-Ig) Enzyme-linked Immunosorbent Assay (ELISA)	Year 5	1937.4 titer
NOR-204: GI.1/GII.4 (15/50/500) µg - MPL 15 µg, 1-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GI.1 VLP Antibodies as Measured by Total Immunoglobulin (Pan-Ig) Enzyme-linked Immunosorbent Assay (ELISA)	Day 57	10684.3 titer
NOR-204: GI.1/GII.4 (15/50/500) µg - MPL 15 µg, 1-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GI.1 VLP Antibodies as Measured by Total Immunoglobulin (Pan-Ig) Enzyme-linked Immunosorbent Assay (ELISA)	Day 211	5970.0 titer
NOR-204: GI.1/GII.4 (15/50/500) µg - MPL 15 µg, 1-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GI.1 VLP Antibodies as Measured by Total Immunoglobulin (Pan-Ig) Enzyme-linked Immunosorbent Assay (ELISA)	Day 29	630.6 titer
NOR-204: GI.1/GII.4 (15/50/500) µg - MPL 15 µg, 1-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GI.1 VLP Antibodies as Measured by Total Immunoglobulin (Pan-Ig) Enzyme-linked Immunosorbent Assay (ELISA)	Year 4	1512.1 titer
NOR-204: GI.1/GII.4 (15/50/500) µg, 1-Dose (Age: 60-94 Yrs)	Geometric Mean Titers (GMT) of Anti-norovirus GI.1 VLP Antibodies as Measured by Total Immunoglobulin (Pan-Ig) Enzyme-linked Immunosorbent Assay (ELISA)	Year 3	1932.8 titer
NOR-204: GI.1/GII.4 (15/50/500) µg, 1-Dose (Age: 60-94 Yrs)	Geometric Mean Titers (GMT) of Anti-norovirus GI.1 VLP Antibodies as Measured by Total Immunoglobulin (Pan-Ig) Enzyme-linked Immunosorbent Assay (ELISA)	Year 4	1441.7 titer
NOR-204: GI.1/GII.4 (15/50/500) µg, 1-Dose (Age: 60-94 Yrs)	Geometric Mean Titers (GMT) of Anti-norovirus GI.1 VLP Antibodies as Measured by Total Immunoglobulin (Pan-Ig) Enzyme-linked Immunosorbent Assay (ELISA)	Day 57	5646.8 titer
NOR-204: GI.1/GII.4 (15/50/500) µg, 1-Dose (Age: 60-94 Yrs)	Geometric Mean Titers (GMT) of Anti-norovirus GI.1 VLP Antibodies as Measured by Total Immunoglobulin (Pan-Ig) Enzyme-linked Immunosorbent Assay (ELISA)	Day 36	3909.4 titer
NOR-204: GI.1/GII.4 (15/50/500) µg, 1-Dose (Age: 60-94 Yrs)	Geometric Mean Titers (GMT) of Anti-norovirus GI.1 VLP Antibodies as Measured by Total Immunoglobulin (Pan-Ig) Enzyme-linked Immunosorbent Assay (ELISA)	Year 5	1255.5 titer
NOR-204: GI.1/GII.4 (15/50/500) µg, 1-Dose (Age: 60-94 Yrs)	Geometric Mean Titers (GMT) of Anti-norovirus GI.1 VLP Antibodies as Measured by Total Immunoglobulin (Pan-Ig) Enzyme-linked Immunosorbent Assay (ELISA)	Baseline	769.8 titer
NOR-204: GI.1/GII.4 (15/50/500) µg, 1-Dose (Age: 60-94 Yrs)	Geometric Mean Titers (GMT) of Anti-norovirus GI.1 VLP Antibodies as Measured by Total Immunoglobulin (Pan-Ig) Enzyme-linked Immunosorbent Assay (ELISA)	Day 29	734.8 titer
NOR-204: GI.1/GII.4 (15/50/500) µg, 1-Dose (Age: 60-94 Yrs)	Geometric Mean Titers (GMT) of Anti-norovirus GI.1 VLP Antibodies as Measured by Total Immunoglobulin (Pan-Ig) Enzyme-linked Immunosorbent Assay (ELISA)	Year 2	1477.4 titer
NOR-204: GI.1/GII.4 (15/50/500) µg, 1-Dose (Age: 60-94 Yrs)	Geometric Mean Titers (GMT) of Anti-norovirus GI.1 VLP Antibodies as Measured by Total Immunoglobulin (Pan-Ig) Enzyme-linked Immunosorbent Assay (ELISA)	Day 211	4137.3 titer
NOR-204: GI.1/GII.4 (15/50/500) µg, 1-Dose (Age: 18-49 Yrs)	Geometric Mean Titers (GMT) of Anti-norovirus GI.1 VLP Antibodies as Measured by Total Immunoglobulin (Pan-Ig) Enzyme-linked Immunosorbent Assay (ELISA)	Year 3	1254.9 titer
NOR-204: GI.1/GII.4 (15/50/500) µg, 1-Dose (Age: 18-49 Yrs)	Geometric Mean Titers (GMT) of Anti-norovirus GI.1 VLP Antibodies as Measured by Total Immunoglobulin (Pan-Ig) Enzyme-linked Immunosorbent Assay (ELISA)	Year 4	1238.3 titer
NOR-204: GI.1/GII.4 (15/50/500) µg, 1-Dose (Age: 18-49 Yrs)	Geometric Mean Titers (GMT) of Anti-norovirus GI.1 VLP Antibodies as Measured by Total Immunoglobulin (Pan-Ig) Enzyme-linked Immunosorbent Assay (ELISA)	Day 211	3745.8 titer
NOR-204: GI.1/GII.4 (15/50/500) µg, 1-Dose (Age: 18-49 Yrs)	Geometric Mean Titers (GMT) of Anti-norovirus GI.1 VLP Antibodies as Measured by Total Immunoglobulin (Pan-Ig) Enzyme-linked Immunosorbent Assay (ELISA)	Baseline	493.1 titer
NOR-204: GI.1/GII.4 (15/50/500) µg, 1-Dose (Age: 18-49 Yrs)	Geometric Mean Titers (GMT) of Anti-norovirus GI.1 VLP Antibodies as Measured by Total Immunoglobulin (Pan-Ig) Enzyme-linked Immunosorbent Assay (ELISA)	Day 36	7407.6 titer
NOR-204: GI.1/GII.4 (15/50/500) µg, 1-Dose (Age: 18-49 Yrs)	Geometric Mean Titers (GMT) of Anti-norovirus GI.1 VLP Antibodies as Measured by Total Immunoglobulin (Pan-Ig) Enzyme-linked Immunosorbent Assay (ELISA)	Day 29	694.7 titer
NOR-204: GI.1/GII.4 (15/50/500) µg, 1-Dose (Age: 18-49 Yrs)	Geometric Mean Titers (GMT) of Anti-norovirus GI.1 VLP Antibodies as Measured by Total Immunoglobulin (Pan-Ig) Enzyme-linked Immunosorbent Assay (ELISA)	Year 5	1048.6 titer
NOR-204: GI.1/GII.4 (15/50/500) µg, 1-Dose (Age: 18-49 Yrs)	Geometric Mean Titers (GMT) of Anti-norovirus GI.1 VLP Antibodies as Measured by Total Immunoglobulin (Pan-Ig) Enzyme-linked Immunosorbent Assay (ELISA)	Day 57	7944.8 titer
NOR-204: GI.1/GII.4 (15/50/500) µg, 1-Dose (Age: 18-49 Yrs)	Geometric Mean Titers (GMT) of Anti-norovirus GI.1 VLP Antibodies as Measured by Total Immunoglobulin (Pan-Ig) Enzyme-linked Immunosorbent Assay (ELISA)	Year 2	1672.4 titer
NOR-204: GI.1/GII.4 (15/50/500) µg - MPL 15 µg, 2-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GI.1 VLP Antibodies as Measured by Total Immunoglobulin (Pan-Ig) Enzyme-linked Immunosorbent Assay (ELISA)	Year 5	2060.5 titer
NOR-204: GI.1/GII.4 (15/50/500) µg - MPL 15 µg, 2-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GI.1 VLP Antibodies as Measured by Total Immunoglobulin (Pan-Ig) Enzyme-linked Immunosorbent Assay (ELISA)	Year 3	1670.1 titer
NOR-204: GI.1/GII.4 (15/50/500) µg - MPL 15 µg, 2-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GI.1 VLP Antibodies as Measured by Total Immunoglobulin (Pan-Ig) Enzyme-linked Immunosorbent Assay (ELISA)	Year 2	1770.6 titer
NOR-204: GI.1/GII.4 (15/50/500) µg - MPL 15 µg, 2-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GI.1 VLP Antibodies as Measured by Total Immunoglobulin (Pan-Ig) Enzyme-linked Immunosorbent Assay (ELISA)	Day 211	5320.5 titer
NOR-204: GI.1/GII.4 (15/50/500) µg - MPL 15 µg, 2-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GI.1 VLP Antibodies as Measured by Total Immunoglobulin (Pan-Ig) Enzyme-linked Immunosorbent Assay (ELISA)	Day 57	9388.2 titer
NOR-204: GI.1/GII.4 (15/50/500) µg - MPL 15 µg, 2-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GI.1 VLP Antibodies as Measured by Total Immunoglobulin (Pan-Ig) Enzyme-linked Immunosorbent Assay (ELISA)	Baseline	683.8 titer
NOR-204: GI.1/GII.4 (15/50/500) µg - MPL 15 µg, 2-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GI.1 VLP Antibodies as Measured by Total Immunoglobulin (Pan-Ig) Enzyme-linked Immunosorbent Assay (ELISA)	Day 29	10862.2 titer
NOR-204: GI.1/GII.4 (15/50/500) µg - MPL 15 µg, 2-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GI.1 VLP Antibodies as Measured by Total Immunoglobulin (Pan-Ig) Enzyme-linked Immunosorbent Assay (ELISA)	Year 4	1585.6 titer
NOR-204: GI.1/GII.4 (15/50/500) µg - MPL 15 µg, 2-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GI.1 VLP Antibodies as Measured by Total Immunoglobulin (Pan-Ig) Enzyme-linked Immunosorbent Assay (ELISA)	Day 36	10851.2 titer
NOR-204: GI.1/GII.4 (15/50/500) µg, 2-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GI.1 VLP Antibodies as Measured by Total Immunoglobulin (Pan-Ig) Enzyme-linked Immunosorbent Assay (ELISA)	Year 4	1392.4 titer
NOR-204: GI.1/GII.4 (15/50/500) µg, 2-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GI.1 VLP Antibodies as Measured by Total Immunoglobulin (Pan-Ig) Enzyme-linked Immunosorbent Assay (ELISA)	Day 211	5020.4 titer
NOR-204: GI.1/GII.4 (15/50/500) µg, 2-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GI.1 VLP Antibodies as Measured by Total Immunoglobulin (Pan-Ig) Enzyme-linked Immunosorbent Assay (ELISA)	Year 2	1635.0 titer
NOR-204: GI.1/GII.4 (15/50/500) µg, 2-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GI.1 VLP Antibodies as Measured by Total Immunoglobulin (Pan-Ig) Enzyme-linked Immunosorbent Assay (ELISA)	Year 5	1687.2 titer
NOR-204: GI.1/GII.4 (15/50/500) µg, 2-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GI.1 VLP Antibodies as Measured by Total Immunoglobulin (Pan-Ig) Enzyme-linked Immunosorbent Assay (ELISA)	Day 36	8143.0 titer
NOR-204: GI.1/GII.4 (15/50/500) µg, 2-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GI.1 VLP Antibodies as Measured by Total Immunoglobulin (Pan-Ig) Enzyme-linked Immunosorbent Assay (ELISA)	Day 29	8286.7 titer
NOR-204: GI.1/GII.4 (15/50/500) µg, 2-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GI.1 VLP Antibodies as Measured by Total Immunoglobulin (Pan-Ig) Enzyme-linked Immunosorbent Assay (ELISA)	Day 57	7316.3 titer
NOR-204: GI.1/GII.4 (15/50/500) µg, 2-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GI.1 VLP Antibodies as Measured by Total Immunoglobulin (Pan-Ig) Enzyme-linked Immunosorbent Assay (ELISA)	Baseline	851.8 titer
NOR-204: GI.1/GII.4 (15/50/500) µg, 2-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GI.1 VLP Antibodies as Measured by Total Immunoglobulin (Pan-Ig) Enzyme-linked Immunosorbent Assay (ELISA)	Year 3	1700.5 titer

Secondary

Geometric Mean Titers (GMT) of Anti-norovirus GII.4 VLP Antibodies as Measured by Pan-Ig ELISA

GMT of anti-norovirus GII.4 VLP antibody titers as measured by pan-Ig ELISA. Data reported for up to Year 5 was collected at Baseline (NOR-107,NOR-210, NOR-204), at Days 28 (NOR-107), 29 (NOR-204 and NOR-210), Day 36 (NOR-204), Day 56 (NOR-107) and Day 57 (NOR-204), Day 208 (NOR-107) and Day 211 (NOR-204), Year 2 (NOR-204 and NOR-210) Years 3, 4 and 5 (NOR-107,NOR-210, NOR-204).

Time frame: Baseline up to Year 2 post-primary vaccination of initial study NOR-107, NOR-210 NOR-204 and up to Year 5 of this extension study

Arm	Measure	Group	Value (GEOMETRIC_MEAN)
NOR-107: GI.1/GII.4 (15/15/500) μg- MPL 50 μg,1-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GII.4 VLP Antibodies as Measured by Pan-Ig ELISA	Year 3	1643.9 titer
NOR-107: GI.1/GII.4 (15/15/500) μg- MPL 50 μg,1-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GII.4 VLP Antibodies as Measured by Pan-Ig ELISA	Baseline	1209.8 titer
NOR-107: GI.1/GII.4 (15/15/500) μg- MPL 50 μg,1-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GII.4 VLP Antibodies as Measured by Pan-Ig ELISA	Day 56	5051.3 titer
NOR-107: GI.1/GII.4 (15/15/500) μg- MPL 50 μg,1-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GII.4 VLP Antibodies as Measured by Pan-Ig ELISA	Day 28	1218.3 titer
NOR-107: GI.1/GII.4 (15/15/500) μg- MPL 50 μg,1-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GII.4 VLP Antibodies as Measured by Pan-Ig ELISA	Year 4	1580.2 titer
NOR-107: GI.1/GII.4 (15/15/500) μg- MPL 50 μg,1-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GII.4 VLP Antibodies as Measured by Pan-Ig ELISA	Day 208	2805.0 titer
NOR-107: GI.1/GII.4 (15/15/500) μg- MPL 50 μg,1-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GII.4 VLP Antibodies as Measured by Pan-Ig ELISA	Year 5	1159.9 titer
NOR-107: GI.1/GII.4 (15/50/500) μg- MPL 50 μg,1-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GII.4 VLP Antibodies as Measured by Pan-Ig ELISA	Year 4	2128.6 titer
NOR-107: GI.1/GII.4 (15/50/500) μg- MPL 50 μg,1-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GII.4 VLP Antibodies as Measured by Pan-Ig ELISA	Day 208	3797.7 titer
NOR-107: GI.1/GII.4 (15/50/500) μg- MPL 50 μg,1-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GII.4 VLP Antibodies as Measured by Pan-Ig ELISA	Baseline	1248.3 titer
NOR-107: GI.1/GII.4 (15/50/500) μg- MPL 50 μg,1-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GII.4 VLP Antibodies as Measured by Pan-Ig ELISA	Year 3	1874.7 titer
NOR-107: GI.1/GII.4 (15/50/500) μg- MPL 50 μg,1-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GII.4 VLP Antibodies as Measured by Pan-Ig ELISA	Year 5	2232.6 titer
NOR-107: GI.1/GII.4 (15/50/500) μg- MPL 50 μg,1-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GII.4 VLP Antibodies as Measured by Pan-Ig ELISA	Day 28	1233.2 titer
NOR-107: GI.1/GII.4 (15/50/500) μg- MPL 50 μg,1-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GII.4 VLP Antibodies as Measured by Pan-Ig ELISA	Day 56	8644.5 titer
NOR-107: GI.1/GII.4 (50/50/500) μg- MPL 50 μg,1-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GII.4 VLP Antibodies as Measured by Pan-Ig ELISA	Baseline	1423.3 titer
NOR-107: GI.1/GII.4 (50/50/500) μg- MPL 50 μg,1-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GII.4 VLP Antibodies as Measured by Pan-Ig ELISA	Year 3	1756.7 titer
NOR-107: GI.1/GII.4 (50/50/500) μg- MPL 50 μg,1-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GII.4 VLP Antibodies as Measured by Pan-Ig ELISA	Day 208	2757.9 titer
NOR-107: GI.1/GII.4 (50/50/500) μg- MPL 50 μg,1-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GII.4 VLP Antibodies as Measured by Pan-Ig ELISA	Year 5	1702.6 titer
NOR-107: GI.1/GII.4 (50/50/500) μg- MPL 50 μg,1-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GII.4 VLP Antibodies as Measured by Pan-Ig ELISA	Year 4	1828.6 titer
NOR-107: GI.1/GII.4 (50/50/500) μg- MPL 50 μg,1-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GII.4 VLP Antibodies as Measured by Pan-Ig ELISA	Day 56	5651.7 titer
NOR-107: GI.1/GII.4 (50/50/500) μg- MPL 50 μg,1-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GII.4 VLP Antibodies as Measured by Pan-Ig ELISA	Day 28	1471.1 titer
NOR-107: GI.1/GII.4 (15/15/500) μg- MPL 15 μg,1-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GII.4 VLP Antibodies as Measured by Pan-Ig ELISA	Year 3	1159.4 titer
NOR-107: GI.1/GII.4 (15/15/500) μg- MPL 15 μg,1-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GII.4 VLP Antibodies as Measured by Pan-Ig ELISA	Day 28	953.8 titer
NOR-107: GI.1/GII.4 (15/15/500) μg- MPL 15 μg,1-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GII.4 VLP Antibodies as Measured by Pan-Ig ELISA	Baseline	954.0 titer
NOR-107: GI.1/GII.4 (15/15/500) μg- MPL 15 μg,1-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GII.4 VLP Antibodies as Measured by Pan-Ig ELISA	Day 208	2575.3 titer
NOR-107: GI.1/GII.4 (15/15/500) μg- MPL 15 μg,1-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GII.4 VLP Antibodies as Measured by Pan-Ig ELISA	Year 5	1135.0 titer
NOR-107: GI.1/GII.4 (15/15/500) μg- MPL 15 μg,1-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GII.4 VLP Antibodies as Measured by Pan-Ig ELISA	Day 56	3909.2 titer
NOR-107: GI.1/GII.4 (15/15/500) μg- MPL 15 μg,1-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GII.4 VLP Antibodies as Measured by Pan-Ig ELISA	Year 4	1234.2 titer
NOR-107: GI.1/GII.4 (15/50/500) μg- MPL 15 μg,1-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GII.4 VLP Antibodies as Measured by Pan-Ig ELISA	Day 208	2861.7 titer
NOR-107: GI.1/GII.4 (15/50/500) μg- MPL 15 μg,1-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GII.4 VLP Antibodies as Measured by Pan-Ig ELISA	Year 3	1193.5 titer
NOR-107: GI.1/GII.4 (15/50/500) μg- MPL 15 μg,1-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GII.4 VLP Antibodies as Measured by Pan-Ig ELISA	Year 5	1177.1 titer
NOR-107: GI.1/GII.4 (15/50/500) μg- MPL 15 μg,1-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GII.4 VLP Antibodies as Measured by Pan-Ig ELISA	Year 4	1283.8 titer
NOR-107: GI.1/GII.4 (15/50/500) μg- MPL 15 μg,1-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GII.4 VLP Antibodies as Measured by Pan-Ig ELISA	Day 28	754.4 titer
NOR-107: GI.1/GII.4 (15/50/500) μg- MPL 15 μg,1-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GII.4 VLP Antibodies as Measured by Pan-Ig ELISA	Baseline	838.8 titer
NOR-107: GI.1/GII.4 (15/50/500) μg- MPL 15 μg,1-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GII.4 VLP Antibodies as Measured by Pan-Ig ELISA	Day 56	6655.7 titer
NOR-107: GI.1/GII.4 (50/50/500) μg- MPL 15 μg,1-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GII.4 VLP Antibodies as Measured by Pan-Ig ELISA	Day 208	3086.6 titer
NOR-107: GI.1/GII.4 (50/50/500) μg- MPL 15 μg,1-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GII.4 VLP Antibodies as Measured by Pan-Ig ELISA	Baseline	1239.7 titer
NOR-107: GI.1/GII.4 (50/50/500) μg- MPL 15 μg,1-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GII.4 VLP Antibodies as Measured by Pan-Ig ELISA	Year 5	1545.6 titer
NOR-107: GI.1/GII.4 (50/50/500) μg- MPL 15 μg,1-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GII.4 VLP Antibodies as Measured by Pan-Ig ELISA	Day 28	1198.8 titer
NOR-107: GI.1/GII.4 (50/50/500) μg- MPL 15 μg,1-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GII.4 VLP Antibodies as Measured by Pan-Ig ELISA	Year 4	1714.5 titer
NOR-107: GI.1/GII.4 (50/50/500) μg- MPL 15 μg,1-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GII.4 VLP Antibodies as Measured by Pan-Ig ELISA	Day 56	7585.7 titer
NOR-107: GI.1/GII.4 (50/50/500) μg- MPL 15 μg,1-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GII.4 VLP Antibodies as Measured by Pan-Ig ELISA	Year 3	1385.2 titer
NOR-107: GI.1/GII.4 (15/15/500) μg,1-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GII.4 VLP Antibodies as Measured by Pan-Ig ELISA	Day 28	1310.7 titer
NOR-107: GI.1/GII.4 (15/15/500) μg,1-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GII.4 VLP Antibodies as Measured by Pan-Ig ELISA	Baseline	1373.7 titer
NOR-107: GI.1/GII.4 (15/15/500) μg,1-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GII.4 VLP Antibodies as Measured by Pan-Ig ELISA	Day 56	3296.3 titer
NOR-107: GI.1/GII.4 (15/15/500) μg,1-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GII.4 VLP Antibodies as Measured by Pan-Ig ELISA	Day 208	2239.3 titer
NOR-107: GI.1/GII.4 (15/15/500) μg,1-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GII.4 VLP Antibodies as Measured by Pan-Ig ELISA	Year 3	1425.3 titer
NOR-107: GI.1/GII.4 (15/15/500) μg,1-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GII.4 VLP Antibodies as Measured by Pan-Ig ELISA	Year 5	1410.6 titer
NOR-107: GI.1/GII.4 (15/15/500) μg,1-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GII.4 VLP Antibodies as Measured by Pan-Ig ELISA	Year 4	2114.3 titer
NOR-107: GI.1/GII.4 (15/50/500) μg,1-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GII.4 VLP Antibodies as Measured by Pan-Ig ELISA	Year 4	1858.2 titer
NOR-107: GI.1/GII.4 (15/50/500) μg,1-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GII.4 VLP Antibodies as Measured by Pan-Ig ELISA	Day 28	1246.3 titer
NOR-107: GI.1/GII.4 (15/50/500) μg,1-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GII.4 VLP Antibodies as Measured by Pan-Ig ELISA	Day 208	4668.9 titer
NOR-107: GI.1/GII.4 (15/50/500) μg,1-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GII.4 VLP Antibodies as Measured by Pan-Ig ELISA	Day 56	9110.9 titer
NOR-107: GI.1/GII.4 (15/50/500) μg,1-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GII.4 VLP Antibodies as Measured by Pan-Ig ELISA	Year 3	1705.3 titer
NOR-107: GI.1/GII.4 (15/50/500) μg,1-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GII.4 VLP Antibodies as Measured by Pan-Ig ELISA	Year 5	2047.9 titer
NOR-107: GI.1/GII.4 (15/50/500) μg,1-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GII.4 VLP Antibodies as Measured by Pan-Ig ELISA	Baseline	1179.5 titer
NOR-107: GI.1/GII.4 (50/50/500) μg,1-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GII.4 VLP Antibodies as Measured by Pan-Ig ELISA	Day 208	2349.9 titer
NOR-107: GI.1/GII.4 (50/50/500) μg,1-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GII.4 VLP Antibodies as Measured by Pan-Ig ELISA	Year 3	1166.5 titer
NOR-107: GI.1/GII.4 (50/50/500) μg,1-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GII.4 VLP Antibodies as Measured by Pan-Ig ELISA	Baseline	1133.9 titer
NOR-107: GI.1/GII.4 (50/50/500) μg,1-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GII.4 VLP Antibodies as Measured by Pan-Ig ELISA	Year 4	1115.2 titer
NOR-107: GI.1/GII.4 (50/50/500) μg,1-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GII.4 VLP Antibodies as Measured by Pan-Ig ELISA	Year 5	1265.5 titer
NOR-107: GI.1/GII.4 (50/50/500) μg,1-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GII.4 VLP Antibodies as Measured by Pan-Ig ELISA	Day 56	4762.7 titer
NOR-107: GI.1/GII.4 (50/50/500) μg,1-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GII.4 VLP Antibodies as Measured by Pan-Ig ELISA	Day 28	1086.0 titer
NOR-107: GI.1/GII.4 (50/150/500) μg,1-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GII.4 VLP Antibodies as Measured by Pan-Ig ELISA	Day 28	1491.7 titer
NOR-107: GI.1/GII.4 (50/150/500) μg,1-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GII.4 VLP Antibodies as Measured by Pan-Ig ELISA	Day 56	10733.0 titer
NOR-107: GI.1/GII.4 (50/150/500) μg,1-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GII.4 VLP Antibodies as Measured by Pan-Ig ELISA	Year 3	1775.4 titer
NOR-107: GI.1/GII.4 (50/150/500) μg,1-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GII.4 VLP Antibodies as Measured by Pan-Ig ELISA	Year 4	1762.5 titer
NOR-107: GI.1/GII.4 (50/150/500) μg,1-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GII.4 VLP Antibodies as Measured by Pan-Ig ELISA	Baseline	1442.1 titer
NOR-107: GI.1/GII.4 (50/150/500) μg,1-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GII.4 VLP Antibodies as Measured by Pan-Ig ELISA	Year 5	2037.4 titer
NOR-107: GI.1/GII.4 (50/150/500) μg,1-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GII.4 VLP Antibodies as Measured by Pan-Ig ELISA	Day 208	4661.9 titer
NOR-107: GI.1/GII.4 (15/50/167) μg,1-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GII.4 VLP Antibodies as Measured by Pan-Ig ELISA	Day 208	4450.1 titer
NOR-107: GI.1/GII.4 (15/50/167) μg,1-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GII.4 VLP Antibodies as Measured by Pan-Ig ELISA	Day 28	1940.6 titer
NOR-107: GI.1/GII.4 (15/50/167) μg,1-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GII.4 VLP Antibodies as Measured by Pan-Ig ELISA	Baseline	2069.2 titer
NOR-107: GI.1/GII.4 (15/50/167) μg,1-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GII.4 VLP Antibodies as Measured by Pan-Ig ELISA	Day 56	9544.8 titer
NOR-107: GI.1/GII.4 (15/50/167) μg,1-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GII.4 VLP Antibodies as Measured by Pan-Ig ELISA	Year 3	1783.7 titer
NOR-107: GI.1/GII.4 (15/50/167) μg,1-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GII.4 VLP Antibodies as Measured by Pan-Ig ELISA	Year 4	2173.9 titer
NOR-107: GI.1/GII.4 (15/50/167) μg,1-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GII.4 VLP Antibodies as Measured by Pan-Ig ELISA	Year 5	1648.1 titer
NOR-107: GI.1/GII.4 (15/50/500) μg,2-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GII.4 VLP Antibodies as Measured by Pan-Ig ELISA	Year 4	1702.1 titer
NOR-107: GI.1/GII.4 (15/50/500) μg,2-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GII.4 VLP Antibodies as Measured by Pan-Ig ELISA	Day 28	8866.0 titer
NOR-107: GI.1/GII.4 (15/50/500) μg,2-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GII.4 VLP Antibodies as Measured by Pan-Ig ELISA	Year 3	1880.8 titer
NOR-107: GI.1/GII.4 (15/50/500) μg,2-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GII.4 VLP Antibodies as Measured by Pan-Ig ELISA	Year 5	1746.6 titer
NOR-107: GI.1/GII.4 (15/50/500) μg,2-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GII.4 VLP Antibodies as Measured by Pan-Ig ELISA	Baseline	1078.9 titer
NOR-107: GI.1/GII.4 (15/50/500) μg,2-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GII.4 VLP Antibodies as Measured by Pan-Ig ELISA	Day 208	4004.2 titer
NOR-107: GI.1/GII.4 (15/50/500) μg,2-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GII.4 VLP Antibodies as Measured by Pan-Ig ELISA	Day 56	7083.6 titer
NOR-107: GI.1/GII.4 (50/150/500) μg,2-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GII.4 VLP Antibodies as Measured by Pan-Ig ELISA	Day 208	4807.4 titer
NOR-107: GI.1/GII.4 (50/150/500) μg,2-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GII.4 VLP Antibodies as Measured by Pan-Ig ELISA	Year 5	2225.0 titer
NOR-107: GI.1/GII.4 (50/150/500) μg,2-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GII.4 VLP Antibodies as Measured by Pan-Ig ELISA	Baseline	1308.9 titer
NOR-107: GI.1/GII.4 (50/150/500) μg,2-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GII.4 VLP Antibodies as Measured by Pan-Ig ELISA	Day 56	10333.3 titer
NOR-107: GI.1/GII.4 (50/150/500) μg,2-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GII.4 VLP Antibodies as Measured by Pan-Ig ELISA	Year 4	2766.1 titer
NOR-107: GI.1/GII.4 (50/150/500) μg,2-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GII.4 VLP Antibodies as Measured by Pan-Ig ELISA	Year 3	2079.5 titer
NOR-107: GI.1/GII.4 (50/150/500) μg,2-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GII.4 VLP Antibodies as Measured by Pan-Ig ELISA	Day 28	13710.2 titer
NOR-107: GI.1/GII.4 (15/50/167) μg,2-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GII.4 VLP Antibodies as Measured by Pan-Ig ELISA	Day 28	10202.3 titer
NOR-107: GI.1/GII.4 (15/50/167) μg,2-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GII.4 VLP Antibodies as Measured by Pan-Ig ELISA	Year 5	1624.0 titer
NOR-107: GI.1/GII.4 (15/50/167) μg,2-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GII.4 VLP Antibodies as Measured by Pan-Ig ELISA	Year 4	2044.1 titer
NOR-107: GI.1/GII.4 (15/50/167) μg,2-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GII.4 VLP Antibodies as Measured by Pan-Ig ELISA	Day 56	7801.7 titer
NOR-107: GI.1/GII.4 (15/50/167) μg,2-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GII.4 VLP Antibodies as Measured by Pan-Ig ELISA	Year 3	1946.0 titer
NOR-107: GI.1/GII.4 (15/50/167) μg,2-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GII.4 VLP Antibodies as Measured by Pan-Ig ELISA	Baseline	1598.5 titer
NOR-107: GI.1/GII.4 (15/50/167) μg,2-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GII.4 VLP Antibodies as Measured by Pan-Ig ELISA	Day 208	4177.3 titer
NOR-210: GI.1/GII.4 (15/50/500) µg, 1-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GII.4 VLP Antibodies as Measured by Pan-Ig ELISA	Year 3	1202.9 titer
NOR-210: GI.1/GII.4 (15/50/500) µg, 1-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GII.4 VLP Antibodies as Measured by Pan-Ig ELISA	Day 29	10170.0 titer
NOR-210: GI.1/GII.4 (15/50/500) µg, 1-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GII.4 VLP Antibodies as Measured by Pan-Ig ELISA	Year 5	1241.5 titer
NOR-210: GI.1/GII.4 (15/50/500) µg, 1-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GII.4 VLP Antibodies as Measured by Pan-Ig ELISA	Year 2	1513.3 titer
NOR-210: GI.1/GII.4 (15/50/500) µg, 1-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GII.4 VLP Antibodies as Measured by Pan-Ig ELISA	Baseline	93.1 titer
NOR-210: GI.1/GII.4 (15/50/500) µg, 1-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GII.4 VLP Antibodies as Measured by Pan-Ig ELISA	Year 4	1254.0 titer
NOR-204: GI.1/GII.4 (15/50/500) µg - MPL 15 µg, 1-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GII.4 VLP Antibodies as Measured by Pan-Ig ELISA	Year 3	2200.3 titer
NOR-204: GI.1/GII.4 (15/50/500) µg - MPL 15 µg, 1-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GII.4 VLP Antibodies as Measured by Pan-Ig ELISA	Day 211	5710.0 titer
NOR-204: GI.1/GII.4 (15/50/500) µg - MPL 15 µg, 1-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GII.4 VLP Antibodies as Measured by Pan-Ig ELISA	Year 2	2344.8 titer
NOR-204: GI.1/GII.4 (15/50/500) µg - MPL 15 µg, 1-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GII.4 VLP Antibodies as Measured by Pan-Ig ELISA	Day 57	9761.9 titer
NOR-204: GI.1/GII.4 (15/50/500) µg - MPL 15 µg, 1-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GII.4 VLP Antibodies as Measured by Pan-Ig ELISA	Day 36	5938.0 titer
NOR-204: GI.1/GII.4 (15/50/500) µg - MPL 15 µg, 1-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GII.4 VLP Antibodies as Measured by Pan-Ig ELISA	Day 29	1172.6 titer
NOR-204: GI.1/GII.4 (15/50/500) µg - MPL 15 µg, 1-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GII.4 VLP Antibodies as Measured by Pan-Ig ELISA	Year 4	1514.3 titer
NOR-204: GI.1/GII.4 (15/50/500) µg - MPL 15 µg, 1-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GII.4 VLP Antibodies as Measured by Pan-Ig ELISA	Baseline	1213.2 titer
NOR-204: GI.1/GII.4 (15/50/500) µg - MPL 15 µg, 1-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GII.4 VLP Antibodies as Measured by Pan-Ig ELISA	Year 5	1076.0 titer
NOR-204: GI.1/GII.4 (15/50/500) µg, 1-Dose (Age: 60-94 Yrs)	Geometric Mean Titers (GMT) of Anti-norovirus GII.4 VLP Antibodies as Measured by Pan-Ig ELISA	Day 57	5961.1 titer
NOR-204: GI.1/GII.4 (15/50/500) µg, 1-Dose (Age: 60-94 Yrs)	Geometric Mean Titers (GMT) of Anti-norovirus GII.4 VLP Antibodies as Measured by Pan-Ig ELISA	Year 5	912.7 titer
NOR-204: GI.1/GII.4 (15/50/500) µg, 1-Dose (Age: 60-94 Yrs)	Geometric Mean Titers (GMT) of Anti-norovirus GII.4 VLP Antibodies as Measured by Pan-Ig ELISA	Baseline	826.1 titer
NOR-204: GI.1/GII.4 (15/50/500) µg, 1-Dose (Age: 60-94 Yrs)	Geometric Mean Titers (GMT) of Anti-norovirus GII.4 VLP Antibodies as Measured by Pan-Ig ELISA	Year 4	1267.2 titer
NOR-204: GI.1/GII.4 (15/50/500) µg, 1-Dose (Age: 60-94 Yrs)	Geometric Mean Titers (GMT) of Anti-norovirus GII.4 VLP Antibodies as Measured by Pan-Ig ELISA	Year 3	1771.1 titer
NOR-204: GI.1/GII.4 (15/50/500) µg, 1-Dose (Age: 60-94 Yrs)	Geometric Mean Titers (GMT) of Anti-norovirus GII.4 VLP Antibodies as Measured by Pan-Ig ELISA	Day 29	818.6 titer
NOR-204: GI.1/GII.4 (15/50/500) µg, 1-Dose (Age: 60-94 Yrs)	Geometric Mean Titers (GMT) of Anti-norovirus GII.4 VLP Antibodies as Measured by Pan-Ig ELISA	Day 211	3949.0 titer
NOR-204: GI.1/GII.4 (15/50/500) µg, 1-Dose (Age: 60-94 Yrs)	Geometric Mean Titers (GMT) of Anti-norovirus GII.4 VLP Antibodies as Measured by Pan-Ig ELISA	Day 36	4248.1 titer
NOR-204: GI.1/GII.4 (15/50/500) µg, 1-Dose (Age: 60-94 Yrs)	Geometric Mean Titers (GMT) of Anti-norovirus GII.4 VLP Antibodies as Measured by Pan-Ig ELISA	Year 2	1465.5 titer
NOR-204: GI.1/GII.4 (15/50/500) µg, 1-Dose (Age: 18-49 Yrs)	Geometric Mean Titers (GMT) of Anti-norovirus GII.4 VLP Antibodies as Measured by Pan-Ig ELISA	Day 29	1251.3 titer
NOR-204: GI.1/GII.4 (15/50/500) µg, 1-Dose (Age: 18-49 Yrs)	Geometric Mean Titers (GMT) of Anti-norovirus GII.4 VLP Antibodies as Measured by Pan-Ig ELISA	Year 3	2155.0 titer
NOR-204: GI.1/GII.4 (15/50/500) µg, 1-Dose (Age: 18-49 Yrs)	Geometric Mean Titers (GMT) of Anti-norovirus GII.4 VLP Antibodies as Measured by Pan-Ig ELISA	Year 5	1187.7 titer
NOR-204: GI.1/GII.4 (15/50/500) µg, 1-Dose (Age: 18-49 Yrs)	Geometric Mean Titers (GMT) of Anti-norovirus GII.4 VLP Antibodies as Measured by Pan-Ig ELISA	Day 57	8689.8 titer
NOR-204: GI.1/GII.4 (15/50/500) µg, 1-Dose (Age: 18-49 Yrs)	Geometric Mean Titers (GMT) of Anti-norovirus GII.4 VLP Antibodies as Measured by Pan-Ig ELISA	Year 4	1806.5 titer
NOR-204: GI.1/GII.4 (15/50/500) µg, 1-Dose (Age: 18-49 Yrs)	Geometric Mean Titers (GMT) of Anti-norovirus GII.4 VLP Antibodies as Measured by Pan-Ig ELISA	Baseline	1288.0 titer
NOR-204: GI.1/GII.4 (15/50/500) µg, 1-Dose (Age: 18-49 Yrs)	Geometric Mean Titers (GMT) of Anti-norovirus GII.4 VLP Antibodies as Measured by Pan-Ig ELISA	Day 211	4825.8 titer
NOR-204: GI.1/GII.4 (15/50/500) µg, 1-Dose (Age: 18-49 Yrs)	Geometric Mean Titers (GMT) of Anti-norovirus GII.4 VLP Antibodies as Measured by Pan-Ig ELISA	Year 2	4160.4 titer
NOR-204: GI.1/GII.4 (15/50/500) µg, 1-Dose (Age: 18-49 Yrs)	Geometric Mean Titers (GMT) of Anti-norovirus GII.4 VLP Antibodies as Measured by Pan-Ig ELISA	Day 36	8348.3 titer
NOR-204: GI.1/GII.4 (15/50/500) µg - MPL 15 µg, 2-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GII.4 VLP Antibodies as Measured by Pan-Ig ELISA	Baseline	1263.5 titer
NOR-204: GI.1/GII.4 (15/50/500) µg - MPL 15 µg, 2-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GII.4 VLP Antibodies as Measured by Pan-Ig ELISA	Day 211	5389.0 titer
NOR-204: GI.1/GII.4 (15/50/500) µg - MPL 15 µg, 2-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GII.4 VLP Antibodies as Measured by Pan-Ig ELISA	Day 36	9415.5 titer
NOR-204: GI.1/GII.4 (15/50/500) µg - MPL 15 µg, 2-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GII.4 VLP Antibodies as Measured by Pan-Ig ELISA	Day 57	7673.7 titer
NOR-204: GI.1/GII.4 (15/50/500) µg - MPL 15 µg, 2-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GII.4 VLP Antibodies as Measured by Pan-Ig ELISA	Day 29	9284.7 titer
NOR-204: GI.1/GII.4 (15/50/500) µg - MPL 15 µg, 2-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GII.4 VLP Antibodies as Measured by Pan-Ig ELISA	Year 2	2244.0 titer
NOR-204: GI.1/GII.4 (15/50/500) µg - MPL 15 µg, 2-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GII.4 VLP Antibodies as Measured by Pan-Ig ELISA	Year 5	1522.7 titer
NOR-204: GI.1/GII.4 (15/50/500) µg - MPL 15 µg, 2-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GII.4 VLP Antibodies as Measured by Pan-Ig ELISA	Year 4	2466.9 titer
NOR-204: GI.1/GII.4 (15/50/500) µg - MPL 15 µg, 2-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GII.4 VLP Antibodies as Measured by Pan-Ig ELISA	Year 3	2297.5 titer
NOR-204: GI.1/GII.4 (15/50/500) µg, 2-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GII.4 VLP Antibodies as Measured by Pan-Ig ELISA	Baseline	1149.0 titer
NOR-204: GI.1/GII.4 (15/50/500) µg, 2-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GII.4 VLP Antibodies as Measured by Pan-Ig ELISA	Year 4	1823.5 titer
NOR-204: GI.1/GII.4 (15/50/500) µg, 2-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GII.4 VLP Antibodies as Measured by Pan-Ig ELISA	Day 36	8518.7 titer
NOR-204: GI.1/GII.4 (15/50/500) µg, 2-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GII.4 VLP Antibodies as Measured by Pan-Ig ELISA	Day 211	5415.4 titer
NOR-204: GI.1/GII.4 (15/50/500) µg, 2-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GII.4 VLP Antibodies as Measured by Pan-Ig ELISA	Day 57	7610.5 titer
NOR-204: GI.1/GII.4 (15/50/500) µg, 2-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GII.4 VLP Antibodies as Measured by Pan-Ig ELISA	Year 2	2380.4 titer
NOR-204: GI.1/GII.4 (15/50/500) µg, 2-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GII.4 VLP Antibodies as Measured by Pan-Ig ELISA	Day 29	8508.2 titer
NOR-204: GI.1/GII.4 (15/50/500) µg, 2-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GII.4 VLP Antibodies as Measured by Pan-Ig ELISA	Year 3	2304.2 titer
NOR-204: GI.1/GII.4 (15/50/500) µg, 2-Dose	Geometric Mean Titers (GMT) of Anti-norovirus GII.4 VLP Antibodies as Measured by Pan-Ig ELISA	Year 5	2097.3 titer

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026

Long-Term Immunogenicity of the Norovirus GI.1/GII.4 Bivalent Virus-like Particle (VLP) Vaccine (NoV Vaccine) in Adults

Conditions

Keywords

Brief summary

Detailed description

Related papers

Interventions

Sponsors

Study design

Eligibility

Inclusion criteria

Exclusion criteria

Design outcomes

Primary

Secondary

Countries

Participant flow

Participants by arm

Withdrawals & dropouts

Baseline characteristics

Adverse events

Outcome results

Geometric Mean Blocking Titer (GMBT50) of Anti-norovirus GII.4 VLP Antibodies as Measured by HBGA Blocking Assay

Geometric Mean Blocking Titers 50 Percent (%) (GMBT50) of Anti-norovirus GI.1 VLP Antibodies as Measured by Histo-Blood Group Antigen HBGA Blocking Assay

Geometric Mean Titers (GMT) of Anti-norovirus GI.1 VLP Antibodies as Measured by Total Immunoglobulin (Pan-Ig) Enzyme-linked Immunosorbent Assay (ELISA)

Geometric Mean Titers (GMT) of Anti-norovirus GII.4 VLP Antibodies as Measured by Pan-Ig ELISA